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Drug metabolism is an enzyme-catalyzed process that has major implications for a drug’s 
safety and efficacy. Consequently, evaluating the metabolic properties of a new drug 
candidate is of paramount importance already in the preclinical phase of drug development.
Although the available in vitro techniques for drug metabolism research have improved 
over recent years, the state-of-the-art methodology relies on enzyme assays conducted in 
static conditions, with limited spatiotemporal control of assay variables. Conducting
metabolic assays under flow-through conditions could pave the way for more in-depth 
understanding of the mechanistic basis underlying drug-enzyme and drug-drug interactions.
This, however, requires that drug-metabolizing enzymes be immobilized onto a solid 
support material without compromising protein folding or enzyme function. Although a 
wealth of different enzyme immobilization strategies are currently available, most of them 
are not amenable to immobilization of the microsomal, drug-metabolizing enzymes.
The aim of this thesis was to establish immobilized enzyme microreactor (IMER) 
platforms for studying drug metabolism under flow conditions, thereby improving the in
vitro-in vivo prediction of the metabolic fate of new drug candidates. The use of 
microfluidics and microfabrication technology facilitated the straightforward 
implementation of flow-through assays and furthermore allows their multiplexing 
(parallelism) and integration with other operational units on a single platform, minimizing
both reagent consumption and dead volumes.
In the first sub-project (publication I), a novel strategy for the immobilization of the 
membrane-bound enzymes cytochrome P450 (CYP) and UDP-glucuronosyltransferase
(UGT) was designed and implemented on microreactors fabricated from off-stoichiometric 
thiol-enes (OSTE). The strategy was based on biotinylation of human liver microsomes via
biotin-tagged fusogenic liposomes, and utilized the tunable surface chemistry of OSTEs to 
allow easy functionalization of the microreactor surface. The IMER platform was
preliminarily characterized to ascertain enzyme stability and preservation of key enzyme 
kinetic parameters, with an emphasis on CYP-mediated (phase I) oxidoreductive reactions.
In the second sub-project (publication II), the feasibility of the IMER platform for 
studying the kinetics of UGT-mediated drug conjugation (phase II) was assessed, with an
emphasis on the mechanistic basis for the pronounced underestimation of in vivo clearance 
kinetics by the currently available static in vitro techniques. In particular, the effect of 
membrane disruption and fatty-acid inhibition on UGT-kinetics in vitro was studied in 
detail. The kinetics of zidovudine glucuronidation (the model reaction used in this study) 
under flow-through conditions was shown to be in good agreement with that obtained using 
microsomal incubations in static conditions without the need for added pore-forming agents 
such as alamethicin.
In the third sub-project (publication III), the technology was further developed by 
incorporating a highly overlooked dimension in the assay design: the impact of oxygen 
partial pressure on the metabolic fate of drug candidates. This was achieved by exploiting 
the unique material-induced oxygen scavenging property of thiol-ene polymers. The 
developed chip design allowed the rapid and simple control of oxygen concentration in 
enzymatic assays, which is difficult to achieve with conventional static assay methods.
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Overall, the developed methodology was shown to retain enzyme activity and native 
enzyme kinetic parameters of both CYP and UGT enzymes, an unconditional prerequisite 
for drug metabolism assays. With the immobilization method utilizing membrane
biotinylation via liposome fusion, common problems (such as diffusion-limited kinetics and 
enzyme inactivation) associated with conventional immobilization approaches were
circumvented. Furthermore, the universal applicability of the immobilization method for all
membrane-bound enzymes was preliminarily demonstrated with recombinant CYP 
enzymes in sub-project/publication I.
The methodology developed here also enabled mechanistic studies focused on the 
alamethicin-induced membrane disruption (commonly used in UGT assays to overcome 
mass transfer limitations) and the proposed inhibitory effects of fatty acids, which may shed 
light on the foundations behind the poor in vivo correlation associated with UGT reactions 
in vitro.
The material-induced oxygen scavenging facilitated by OSTE polymers, together with 
microfluidic actuation, was shown to be an easily controllable approach for adjusting the 
oxygen partial pressure on demand. The advantage of this approach is that, unlike in typical 
approaches, complex chip designs or pressurized compartments are not needed. Beyond the 
demonstrated feasibility of the IMER platform for studying the impact of NADPH-
cytochrome P450 oxidoreductase (POR)-mediated metabolism, the theoretical framework 
established here for OSTE-enabled oxygen control in microfluidic assays is likely to find 
many applications, particularly in organ-on-a-chip research.
In conclusion, the microreactor platform developed in this thesis offers an enabling 
toolbox for conducting in vitro drug metabolism assays under flow conditions that 
circumvents many of the key shortcomings of current state-of-the-art (static) in vitro
enzyme assay methodology, as well as those of previously reported IMER platforms. At the 
time of publication, the methodology developed herein has already been utilized in several 
follow-up studies and has shown utility in diverse applications beyond this work.
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1 Introduction
Drug development is a notoriously risky and costly undertaking. The process from
discovery of a hit molecule to commercial launch of a drug typically takes over 10 years, 
with costs reaching $1 billion for each successful drug that enters the market.1 A drug 
candidate can fail at any stage of the development pipeline, and most do: About 90% of
drugs that reach the clinical trial phase never make it to the market.2,3
Drug metabolism is an enzyme-catalyzed biotransformation process that plays a major 
role in both the efficacy and safety of a drug in vivo. For example, a drug could be 
metabolized too rapidly for any therapeutic effect to occur. Alternatively, drug metabolism 
could result in the generation of toxic metabolites, or two concomitantly administered drugs 
metabolized via same pathways could interfere with each other’s metabolism, resulting in 
drastic changes in drug exposure. Consequently, the evaluation of the metabolic properties 
of a new drug candidate is of paramount importance and should occur as early as possible 
in the drug development pipeline in order to pinpoint unsuitable candidates before 
undertaking time- and cost-intensive clinical trials.
The current state-of-the-art methodology in drug metabolism research involves enzyme 
assays conducted in static conditions on a well-plate platform, with limited spatiotemporal 
control of assay variables. The development of immobilized enzyme microreactors (IMER)
by the immobilization of drug-metabolizing enzymes would benefit the field of in vitro 
metabolism research in many ways. Most importantly, microreactors allow the possibility 
of performing experiments under flow-through conditions. This enables the precise 
spatiotemporal control of reaction conditions by simply altering the chemical composition 
of the flow, which facilitates determination of enzyme kinetic parameters and mechanistic 
studies of time-dependent drug-drug and drug-enzyme interactions. However, the 
immobilization of membrane-bound enzymes such as members of the cytochrome P450 
(CYP) and UDP-glucuronosyltransferase (UGT) enzyme families (which constitute the 
majority of enzymes responsible for human drug metabolism) has proven difficult: current 
immobilization approaches are not well-suited for these membrane proteins and often result 
in unwanted alterations in enzyme function.
Since the advent of microfluidics some 30 years ago, microfluidic applications have 
found their way into virtually every imaginable field of research, drug development 
included. The ever-increasing interest in microfluidics is based on the intrinsic benefits of 
miniaturization. The manipulation of minute volumes within micrometer or nanometer scale
channels decreases reagent consumption and produces less waste. With modern 
microfabrication technologies, several unit operations can be easily integrated into one 
microfluidic chip to create so-called micro total analysis systems (μTAS), the ultimate goal
of which is to create a streamlined “sample in/answer out” system.
This thesis will discuss the state-of-the-art in the development of flow-through 
microreactors for drug metabolism research, with an emphasis on enzyme immobilization 
and available manufacturing materials and methods. The thesis will also review assay design 
principles, setting the scene for the development of microfluidic flow-through immobilized 
enzyme reactors, the overall aim of this thesis work.
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2 Review of the literature
2.1 Human drug metabolism
In order for a drug to have any clinical effect, it must be absorbed by the body in sufficient 
amounts and distributed across biological barriers to reach therapeutic concentrations in the 
target organ. This is why the majority of clinically used drug molecules are lipophilic in 
nature. Once absorbed in the body, lipophilic substances tend to accumulate in body tissues, 
and thus cannot be straightforwardly excreted from the body via the kidneys or intestines.
Consequently, the main objective of drug metabolism is to render exogenous substances 
more hydrophilic, thus facilitating their elimination through urine or feces. Drug 
metabolism is often associated with loss of pharmacological potency, but can in some cases 
result in the production of toxic or pharmacologically potent metabolites.4
The metabolic pathway of a drug is usually divided into distinct phases. Phase I reactions 
include a variety of functionalization reactions, mostly oxidative in nature, that are catalyzed 
by various classes of enzymes, particularly those of the cytochrome P450 (CYP) 
superfamily.5 Phase I reactions are typically regarded as a preparatory step followed by 
conjugation (phase II) of the newly formed functional group to a hydrophilic moiety (e.g.,
glutathione, glucuronic acid, or sulfate) that further enhances drug hydrophilicity, thus
facilitating excretion through urine or bile. It should be noted, however, that many drugs are 
metabolized only via phase I or phase II reactions, or sometimes even in reverse order. More 
recently, as the importance of biological barriers and membrane transporters in drug efficacy 
and metabolism has become increasingly appreciated, phases 0 (active drug uptake by 
transporters) and III (active drug export by efflux pumps) have been added to the overall 
metabolism scheme.6 As CYPs and UDP-glucuronosyltransferases (UGTs) together are 
responsible for approximately 90% of the metabolism of marketed drugs,7,8 these enzymes
were selected as the focal point of this thesis and were used as the target enzymes for 
immobilization. 
Figure 1 depicts the metabolism of the opioid analgesic drug codeine. The metabolism 
of codeine is a typical example of a metabolic pathway involving both phase I and II 
reactions, and also showcases the importance of metabolism in drug therapy. Codeine is 
first transformed into morphine in a CYP2D6-catalyzed demethylation reaction. Morphine 
is the metabolite responsible for the analgesic effect of codeine, which itself is rather 
pharmacologically inert.9 Patients’ allelic variants of CYP2D6 can have a drastic effect on 
the success of codeine therapy: Those with alleles that dampen CYP2D6 activity will be 
poor metabolizers who experience a lack of analgesic effect; those with alleles that increase 
CYP2D6 activity will be rapid metabolizers who could accumulate hazardous 
concentrations of morphine. Morphine further undergoes phase II metabolism into two 
glucuronide conjugates, morphine-3-glucuronide and morphine-6-glucuronide, that are then 
excreted out of the body through the urine. Interestingly, morphine-6-glucuronide is an even 







Figure 1. Metabolic pathway of the opioid analgesic codeine.  
CYP enzymes are undoubtedly the most important group of drug metabolizing enzymes, 
comprising approximately 75% of metabolism of all marketed drugs.7,8,11 CYPs are heme-
containing monooxygenases that catalyze the oxidation of substrates with an oxygen atom 
derived from molecular oxygen (O2), while reducing the remaining oxygen atom into 
water.12,13 The electrons needed for this reduction reaction are usually supplied in the form 
of nicotinamide adenine dinucleotide phosphate (NADPH), which acts as the co-substrate 
in CYP reactions. The electron transport in CYP reactions is mediated by an auxiliary 
protein called NADPH-cytochrome P450 oxidoreductase (POR), which is obligatory for 
CYP activity.13,14 The heme-containing protein cytochrome b5 is also associated with CYP 
modulation, but its precise role remains unclear.14,15 CYPs, as well as these auxiliary 
proteins, are membrane-bound enzymes located primarily in the endoplasmic reticulum 
(ER) of hepatocytes. The lipid membrane environment is integral to CYP function, affecting 
enzyme conformation and the interaction between CYPs and their redox partners.16 
UDP-glucuronosyltransferases (UGTs) are the most prominent class of enzymes that 
catalyze phase II reactions.7,8 UGTs catalyze the conjugation of a glucuronic acid moiety, 
derived from the cofactor UDP-glucuronic acid (UDPGA), into a suitable functional group 
on a substrate molecule by a glycosidic bond. Similar to CYPs, UGTs are also membrane 
proteins located mainly in the ER of the liver.17 However, unlike CYPs, which reside on the 
cytosolic side of the membrane, the active site of UGTs is located on the luminal side of the 
ER. This complicates the evaluation of data obtained in vitro experiments in ways that will 
be discussed in more detail in section 2.1.2. 
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2.1.1 Metabolism in preclinical drug development
When discovering new chemical entities (NCE), the primary goals of preclinical in vitro
drug metabolism studies are: (1) the assessment of metabolic stability (i.e. susceptibility of 
the NCE to metabolism in general); (2) identification of principal metabolites and the 
enzymes involved in their generation and the kinetics thereof; and (3) assessing the potential 
for drug-drug interactions.18,19 The information gathered from in vitro studies is then
integrated with in vivo data from animal models to predict the fate of the NCE in the human 
body so that no unpleasant surprises—such as toxic metabolites or potentially hazardous
drug interactions—are encountered during clinical trials. This chapter briefly discusses the 
rationale behind the evaluation of in vivo drug metabolism and interaction potential based 
on in vitro experimental data.
Metabolic reactions, like any other enzyme-catalyzed reaction, are usually characterized 
by parameters derived from fitting experimental data into a nonlinear kinetic model, the 
most commonly the Michaelis-Menten model.20 Under steady-state conditions (i.e., no
appreciable depletion of substrate during the reaction and thus no change in the 
concentration of the enzyme-substrate complex20), a reaction obeying Michaelis-Menten 
kinetics can be described by the Equation 1:
(1)
Where v0 is the initial reaction velocity, [S] is the substrate concentration, and KM and Vmax
are reaction-specific constants defining the reaction kinetics. KM, also called the Michaelis 
constant, is determined as the substrate concentration at which half of the maximum reaction 
velocity (Vmax) is reached. Once the major enzymes responsible for the elimination of the 
NCE have been elucidated and the respective kinetic parameters determined, the intrinsic 
clearance (CLint) of the drug can be calculated (assuming non-saturating substrate 
concentrations, i.e. [S] << KM) using Equation 221,22:
(2)
To evaluate in vivo hepatic clearance, the in vitro CLint, expressed in units of L/min/mg 
enzyme (or number of cells in the assay), is first multiplied by a scaling factor to normalize 
the rate of metabolism with respect to the amount of liver tissue in the body. An estimate of 
total hepatic clearance is achieved when the in vivo CLint value is substituted into a liver 
model that takes into account physiological phenomena such as blood flow and mass 
transfer inside the liver.21,22 In addition to hepatic clearance, a drug could have extrahepatic 
elimination routes (such as renal excretion of unchanged drug), and these should be taken 
into consideration in total-body clearance, obtained as a sum of all alternative elimination 
routes.22,23
Drug-drug interactions occur when concomitantly administered drugs interfere with one
another’s metabolism. Most commonly, one drug inhibits the metabolism of another drug, 
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resulting in increased plasma concentrations of the latter, possibly leading to toxic side 
effects.24,25 The CYP enzyme family is particularly prone to interactions owing to their 
broad substrate spectrum combined with narrow substrate specifity.26 Several CYP-
inhibiting drugs have been removed from the market due to severe adverse drug 
reactions.27,28 Therefore, increasing emphasis has been put on identifying possible risks for
adverse drug-drug interactions already in the preclinical phase of drug development.
Enzyme inhibition can be either reversible or irreversible. Reversible inhibition is the more 
common mechanism of the two, and can be further divided into three modalities—
competitive, noncompetitive, and uncompetitive inhibition—depending on whether the 
inhibitor binds directly to the enzyme’s active site (competitive) or elsewhere (non- or
uncompetitive) on the enzyme.8,29 In irreversible inhibition, the inhibitor covalently bonds
to the enzyme’s apoprotein or the heme group, resulting in total loss of enzyme function. In 
this circumstance, enzyme function can only be restored by de novo synthesis of new 
enzyme. Therefore, irreversible enzyme inhibition is an especially unwanted property in an 
NCE. Besides inhibition, drugs can also cause enzyme induction by acting as activators of 
transcription factors regulating the expression metabolic enzymes.30
The simplest and most common way to assess the interaction potential of an NCE is by 
conducting an half maximal inhibitory concentration (IC50) assay, where varying 
concentrations of a test compound are tested for their propensity to inhibit a model reaction
and the concentration causing 50% of maximal inhibition is reported as the IC50 value.31,32
However, IC50 depends on the substrate concentration used in the assay and does not discern 
between different inhibition modalities.33 For a more detailed and unambiguous 
characterization of inhibition, usually further along in the drug development pipeline, the
dissociation constant of the enzyme-inhibitor complex, Ki, should be determined using a 
range of substrate and inhibitor concentrations. With Ki determined, it is possible to predict 
the effect of an inhibitor on the intrinsic clearance using the Equation (3) (shown as an 
example for competitive inhibition):
(3)
Here, [I] represents the concentration of inhibitor at the enzyme active or modulatory site. 
Even if free plasma concentrations of the drug are known, estimating this parameter can be 
challenging because especially lipophilic drugs might concentrate in hepatocytes, far 
exceeding the concentrations found in blood.18
To differentiate between reversible and irreversible (also called mechanism-based) 
inhibition, the inhibitor is preincubated with the enzyme of interest across different time 
intervals.34 If the magnitude of inhibition changes over time, the inhibition is referred to as 
time-dependent inhibition, which often suggests that the inhibition is also mechanism-
based, i.e., irreversible. At this stage, additional experiments are needed to conclusively
verify the mechanism-based and irreversible nature of the inhibition. For example, unlike 
inhibition due to a competitive inhibitor with extremely high affinity or a more potent 
inhibitory metabolite, mechanism-based inhibition cannot be recovered by dialysis.35
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2.1.2 In vitro models
The extrapolation of drug metabolism results from preclinical in vivo animal studies is 
difficult and prone to misinterpretations, given the fundamental differences in metabolism 
between species.36 Specifically, drug metabolism in animal models often results in 
disproportional metabolite ratios or the appearance of completely different metabolites 
compared to what is observed in humans. This is particularly critical when human 
metabolism of a drug results in a toxic metabolite that is not observed in the animal model.
Consequently, in vitro experiments with models based on human-derived material are an 
integral part of preclinical drug metabolism studies. Since metabolism mainly takes place
in the liver due to its high expression levels of drug metabolizing enzymes, most in vitro 
metabolism models are based on liver-derived cells or tissue.19,23,37 It should be noted, 
however, that drug metabolism also takes place in other organs and tissues—particularly
the lungs, kidneys and intestines—that may play a major role in the metabolism of a given 
drug, depending on its characteristics and route of administration.38
The in vitro models used in preclinical studies can be categorized as subcellular, cellular,
and tissue models. All of the available models have a unique set of pros and cons in terms 
of in vivo resemblance, availability, simplicity and economic feasibility, (Table 1).
Table 1. Advantages and disadvantages of different human-derived model systems for the 
study of drug metabolism in vitro.






All metabolic enzymes not 
present
Lack of cell functions (e.g. no 
induction)
Toxicity assays not applicable
Cell lines Good availability
Intact cells
Easy to culture





All metabolic enzymes present





Intact tissue Complete tissue architecture Limited availability
Limited viability
Subcellular fractions—in particular human liver microsomes (HLM)—are considered
the industry standard model for pre-clinical metabolic profiling and drug interaction studies 
because of their relative affordability, availability, and acceptable in vivo
resemblance.31,32,39,40 HLM consist of vesicles of hepatocyte endoplasmic reticulum 
prepared by differential centrifugation.41 HLM contain all the endogenous enzymes 
localized in the ER, namely CYPs, UGTs and flavin monooxygenases (FMOs). Even though 
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these enzymes carry out the majority of human drug metabolism, any metabolites produced 
by other systems (e.g. sulfotransferases, SULTs) cannot be studied with HLM. Furthermore, 
enzymatic activity of HLM can vary substantially between donors, but this problem can be 
overcome by using a pool of liver samples from several donors. For distinguishing which 
enzymes participate in the biotransformation reactions of a given drug, microsomal vesicles 
of isolated, recombinant human enzymes produced in insect cells (marketed under the 
names baculosome or supersome) are commonly used. However, because subcellular 
fractions lack the active gene expression that occurs in intact cells, they cannot be used for 
studying enzyme induction. 
The study of UGT-mediated metabolism using subcellular fractions has certain 
complications, that make it more difficult to extrapolate in vivo metabolism from in vitro
studies.42,43 Namely, because the active sites of UGTs are located on the luminal side of 
microsomes, the membrane forms a physical barrier to the drug substrates and cofactors,
resulting in underestimation of glucuronidation rates (a phenomenon referred to as 
latency).42,44 This problem can be overcome by disrupting the membrane, for example by 
using a pore-forming agent like the peptide antibiotic alamethicin.45 Free fatty acids 
leaching from the microsomal preparations during incubations have also been shown to 
inhibit UGT enzymes, resulting in dramatically altered kinetic parameters.46–48 This
inhibition can be counteracted by sequestering the inhibitory moieties with the addition of 
albumin to the incubation mixture. Even with these modifications to the experimental
protocol, cell-based methods are often more successful—albeit not perfect—in predicting 
in vivo clearances of glucuronidated drugs.49 When using cell models, care should be taken 
that competing metabolic pathways, such as those involving CYPs, do not interfere with the
study of the glucuronidation reaction of interest.40
The most significant advantage of cell models is that they contain the complete 
molecular machinery of the cell— including the presence of all drug-metabolism enzymes,
active gene expression, and intact transport processes—allowing the study of metabolic 
phenomena on a detailed level that is not feasible in subcellular models. Primary 
hepatocytes isolated directly from the human liver are widely used as a model system, owing 
to their strong in vivo resemblance. Cryopreserved primary hepatocytes are also 
commercially available, although they are considerably more expensive than subcellular 
matrices or cell lines. With modern culturing techniques, primary hepatocytes can be 
cultured for several weeks, but cultured cells often suffer from loss of differentiation and 
decline in enzyme expression levels over time.50 Transformed cell lines, either artificially 
transformed or derived from tumor tissue, can be used as a cheaper and more easily 
manageable alternative to primary hepatocytes. However, cell lines often suffer from 
dedifferentiation, which can  result in impaired expression of drug-metabolizing enzymes, 
potentially undermining their applicability in the assessment of drug metabolism.51 It should 
be noted however, that novel culturing methods, such as organ-on-a-chip approaches, have 
been shown to prevent cell dedifferentiation and improve the expression of drug-
metabolizing enzymes in long-term cell cultures.52,53
Intact liver tissue can also be used as an in vitro metabolism model. By definition, tissue-
based models are the most in vivo-like of all the available model systems. Besides enzyme-
containing hepatocytes, tissue models also contain all the non-parenchymal cell types as 
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well as intact cell-to-cell contacts, both of which both are important regulators of tissue 
function.54 The most commonly used tissue model is liver slices prepared with high-
precision tissue slicers.55 The major disadvantage of tissue models is, quite understandably,
their poor availability, and this is further hampered by the lack of reliable cryopreservation 
procedures.32 As with cell models, the activity of metabolic enzymes also declines in tissue 
slices upon culturing.56
For drugs metabolized primarily by CYPs, the use of hepatocytes does not necessarily 
offer a significant advantage over subcellular models.57,58 However, for UGT metabolism, 
cell models have been more successful in predicting in vivo drug clearances.42,49 This might 
be related to the more complicated disposition of highly hydrophilic glucuronides—which 
involve active efflux and influx processes (i.e., metabolic phases 0 and III)—in cell 
models.59 Despite their undeniable advantages, cell-based models are always to some extent 
“black boxes,” where the influence of different mechanistic aspects (i.e., metabolism, 
membrane permeation) on the total outcome cannot always be disentangled.
One relevant shortcoming common to all conventional in vitro models is that the assays 
are performed under an atmospheric, non-physiological oxygen environment. Oxygen 
partial pressure is a crucial factor that affects many biological processes. Oxygen levels in 
the human body vary greatly, with the most oxygenated tissues experiencing oxygen partial 
pressures between 10-13% and the least oxygenated tissues (like the liver and colon) 
experiencing partial pressures of approximately 5%.60 Despite the importance of the oxygen 
microenvironment, most in vitro assays are performed under ambient air (21% O2), with 
oxygen partial pressures not encountered even in the most oxygenated human tissues.60 The 
use of non-physiological oxygen conditions is largely due to the difficulty of oxygen control 
in conventional in vitro platforms such as well plates. The use of  non-physiological oxygen 
conditions can have drastic effects on the behavior of biological samples,61,62 which may 
lead to erroneous interpretations of drug metabolism assay results. The normoxic oxygen 
concentration in a healthy liver is around 40 μM (4%).63,64 For CYPs, oxygen dependency 
varies across substrates and enzyme isoforms. In general, the KO2 values of CYPs (i.e., the 
oxygen concentration resulting in half maximal enzyme activity), are reported to be in the 
range of 10 μM (1%).65–67 This means that under normoxic conditions, most CYPs reactions 
are oxygen-independent but can become limited by oxygen under conditions of mild
hypoxia, known to occur in many physiological conditions. For example, impaired hepatic 
oxygen uptake has been linked to decreased drug clearance in geriatric patients.68 Hypoxia 
is also known to alter the metabolic profile of drugs, as exemplified by the antiviral drug 
zidovudine, which is increasingly converted to a myelotoxic reductive metabolite in hypoxic 
conditions.69 However, the literature on oxygen-dependence of CYP activity is rather 
scarce, presumably due to the lack of feasible methods for the on-demand control of oxygen 
partial pressure in enzymatic assays.
The implementation of immobilized enzyme reactors (IMERs) via the affixing of drug-
metabolizing enzymes would provide several benefits over conventional assays. First, 
immobilization allows for the use of flow conditions. Importantly, this enables the 
spatiotemporal tuning of reaction conditions on demand by simply altering the chemical 
composition of the flow.70 For example, by creating concentration gradients of the substrate,






enzyme inside the reactor also facilitates more straightforward downstream processing, such 
as metabolite purification. The compartmentalized enzyme reaction is also easily combined 
with additional unit operations, such as on-line metabolite detection or a separate cell 
compartment for studying metabolite-induced toxicity.74,75 Given these benefits, the 
immobilization of drug-metabolizing enzymes has been a subject of keen interest for over 
four decades.76,77 However, the fact that the most important classes of drug-metabolizing 
enzymes—namely CYPs and UGTs—are membrane-bound proteins has posed a formidable 
challenge to the field because of several shortcomings with conventional immobilization 
approaches. Enzyme immobilization, both in general and in the special case of membrane-
bound drug-metabolizing enzymes, is discussed in more detail in the next chapter. 
2.2 Enzyme immobilization 
Enzyme immobilization techniques are generally divided into three main categories. 
Enzymes can either be (i) bound to a support material via physical or chemical interactions, 
(ii) entrapped inside a porous matrix, or (iii) cross-linked together to form enzyme 
aggregates or crystals (Figure 2). The pros and cons of each strategy are briefly elaborated 
below. 
 
Figure 2. Schematic representation of different enzyme immobilization approaches (© I. Kiiski 
2020).  
Enzymes can be bound on support materials via both covalent and non-covalent bonds. Non-
covalent methods can be further divided into physical (hydrophobic and van der Waals 
interactions), ionic (electrostatic interactions) and affinity-based (e.g. antibody-mediated 
binding) methods.78,79 
Owing to their low binding energies, non-covalently bound enzymes are easily washed 
away from the carrier surface, especially in more demanding conditions, such as elevated 
temperatures.78,79 On the other hand, weak interactions do not usually alter the tertiary 






immobilization is based on bio-specific interactions between complementary chemical 
species found on the immobilized molecule and the solid support (e.g., between biotin and 
avidin or between an antibody and an antigen).81 While classified as a noncovalent method, 
affinity immobilization can result in binding energies close to those of covalent bonds.82
Affinity immobilization results in very specific bonding that is also reversible in nature, 
which theoretically enables the renewal of the enzyme material. However, affinity-based 
methods usually require modification of the enzyme to introduce the affinity-tag, which can
result in enzyme inactivation. 
Covalent bonding allows for more stable anchorage between the enzyme and the carrier 
surface. When selecting the specific functionality to be used in immobilization, chemical 
compatibility with both the target enzyme and reactor surface must be taken into account.83
Common immobilization chemistries include aldehydes, carboxylic acids, primary amines 
and thiols. All chemistries have specific characteristics (e.g., optimum pH and solubility) 
and must be chosen based on the requirements of the application.84 Traditional covalent 
binding chemistries rely on functional groups naturally present in biomacromolecules (e.g.,
NH2 and COOH) so no prior enzyme modification step is needed. As there is no effective 
control over where the covalent bond between the enzyme and the surface will be formed,
covalent binding methods will generate a heterogeneous population of enzyme due to the 
random orientation of the immobilized biomolecules. This may result in decreased overall 
activity if the substrate’s access to the active site is hindered in some of the immobilized 
enzymes. The steric hindrance associated with covalent immobilization can be overcome by 
distancing the enzyme from the support using a spacer molecule.85 If charged residues are 
used for immobilization, the alteration of protein surface charge can potentially alter enzyme 
activity due to detrimental changes in protein folding.79
Entrapment approaches involve the physical trapping of the enzyme inside a porous 
matrix of synthetic or natural origin. The polymer network is cross-linked in the presence 
of the enzyme, trapping the enzyme inside the matrix due to physical restraints of the 
polymer pore size. Entrapment enables high volumetric enzyme concentrations with 
relatively mild immobilization conditions.86,87 Entrapment can be readily applied to a 
variety of different enzymes, as it is not based on any enzyme-specific properties. Main 
disadvantages of entrapment are enzyme leaching and impaired diffusion.78 Impaired 
diffusion is due to the steric constraints caused by the matrix that affect substrate diffusion 
to the active site of the enzyme. Under these circumstances, enzyme kinetics are usually 
limited by diffusion rather than the velocity of the reaction itself. These alterations should 
be taken into consideration when using IMERs with entrapped enzymes for enzyme kinetic 
characterization.  
Commonly used entrapment matrices include sol-gels and hydrogels.88 Hydrogels are 
more biocompatible than sol-gels and do not require toxic reagents for the polymerization 
process. Most hydrogels are also transparent, which enables the use of various imaging 
techniques. Commonly used hydrogels include synthetics like poly(ethylene glycol) and 
polyacrylamide and natural polymers like chitosan and agarose.
By cross-linking, carrierless macroparticles can be prepared from enzyme aggregates or 
crystals.78,88 The advantage of this technique is that the volumetric enzyme concentration is 
not diluted by the carrier material, as in the case of entrapment techniques. Cross-linking 
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techniques can be divided into two categories according to the physical state of the enzyme 
prior to cross-linking. Cross-linked enzyme crystals (CLECs) are prepared from crystallized 
enzyme with the addition of a bifunctional reagent such as glutaraldehyde. The resulting 
cross-linked crystals are stable and highly active, and their particle size can be readily 
controlled. However, protein crystallization is a laborious procedure that requires high-
purity enzyme. This drawback of CLECs is avoided when enzyme aggregates are used as a 
starting material instead. Subsequent cross-linking of these aggregates generates cross-
linked enzyme aggregates (CLEAs).  As protein precipitation is often used for purification, 
both purification and immobilization can be combined into a single unit operation that can 
be used, for example, to immobilize an enzyme directly from a crude fermentation broth. In 
the context of membrane-bound enzymes, such as CYPs and UGTs, crosslinking is rarely 
used because the protein is embedded inside a lipid membrane. Approaches that have been 
successfully applied to membrane-bound drug-metabolizing enzymes are discussed next in 
more detail.
2.2.1 Immobilization of membrane-bound CYP enzymes
Research on the immobilization of drug-metabolizing enzymes has to-date focused mainly 
on CYP enzymes, while the immobilization of UGTs has received very little attention. This 
is presumably due to the enticing challenges related to the immobilization of CYPs. The 
complex nature of the CYP system, with its multiple membrane-embedded co-operative 
enzymes, places special demands on the immobilization process. Removing of a protein 
from its hydrophobic surroundings and reconstituting it into another is a harsh process that 
is likely to damage the target and result in decreased functionality. With CYPs, this process 
would have to be performed on several proteins (i.e., CYP and its redox partners)
simultaneously, while maintaining their molar ratio and interactions. Several different 
approaches have been described for immobilizing microsomal vesicles and will be 
discussed in detail next with examples from the literature. Though this discussion focuses 
on CYPs, most observations also hold true in the case of any membrane-bound enzyme. 
For HLM, entrapment approaches are most commonly used for immobilization.74,75,89–
92 A probable explanation for the preference of entrapment over other strategies is that it has 
no special demands regarding protein structure and is therefore just as suitable for 
membrane-bound enzymes as it is for other classes of proteins. It could also be argued that 
because the membrane-bound enzymes are embedded within the phospholipid membrane, 
the efficiency of covalent immobilization methods based on the chemistry of amino acids is 
diminished. 
Zguris et al.89 immobilized human liver microsomes in microfluidic channels by 
entrapment in poly(ethylene) glycol. The hydrogel matrix was microstructured by 
photolithography to create CYP arrays that facilitated mass transfer between the flow-
through solution and the CYP-matrix. The immobilization process was shown not to disrupt
CYP activity. However, the enzyme kinetics of the immobilized CYPs were not studied. It 
can be hypothesized that in this configuration the hydrogel matrix imposes diffusional 
constraints that would affect the enzyme kinetics of the immobilized enzymes.
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Sakai-Kato et al.90 used sol-gel chemistry with aqueous silicate as a starting material to 
entrap human liver microsomes into a microarray on a glass surface. The shelf life of the 
HLM was drastically improved compared to that of the soluble enzyme (weeks vs. days). 
The KM value of testosterone 6β-hydroxylation via CYP3A4 in immobilized HLM was also 
determined and found to be slightly higher compared to that of nonimmobilized HLM. As 
explained in the previous chapter, this is likely due to the steric constraints inherent in
entrapment-based immobilization.
Wu et al.93 reported another entrapment strategy in which HLM was immobilized in a 
microwell interconnected to a microfluidic channel by placing a polycarbonate membrane 
with 0.4 μm pores on the bottom of the well. The pores were small enough to restrain the 
microsomes while also permitting molecular transport. The researchers claimed that the
physical immobilization procedure did not cause any enzyme inactivation, but the study did 
not present any data on enzyme stability or kinetics to support this claim.
Besides HLM, similar enzyme entrapment strategies have also been applied to animal-
derived enzyme sources. Lee et al.92,94 immobilized rat liver microsomes inside a
poly(dimethyl siloxane) (PDMS) microchannel by embedding an array of PEG-hydrogel 
pillars inside the channel. As expected, the entrapment of microsomes inside the hydrogel 
resulted in diffusion-limited enzyme kinetics, increasing the apparent KM and decreasing the 
apparent Vmax of the model reaction. The authors speculated that the limited diffusion could 
be mitigated by design revision—that is, reducing the hydrogel pillar diameter and 
increasing the hydrogel porosity. However, no experimental evidence on this was presented
and it can be hypothesized that a looser entrapment matrix might result in enzyme leaching 
out of the microreactor. 
Membrane-bound CYPs have also been immobilized on lipid bilayers on solid supports.
This approach is similar to entrapment in the sense that it targets the whole microsomal 
vesicle rather than just the CYP enzyme and does not involve the use of a molecular tag or 
linker incorporated into the protein structure. Ueda et al.95 immobilized recombinant CYP 
microsomal vesicles on the surface of micropatterned lipid bilayer membranes on glass 
substrates. The patterned lipid surface used for the immobilization was composed of fluid 
membrane islets confined in a framework of rigid polymerized lipid domains. The 
microsomal vesicles were immobilized by membrane fusion with the fluid bilayers induced 
by the lipid composition of the bilayer on the substrate surface. When compared with direct 
adsorption of microsomes on a glass substrate, the enzymes immobilized on the lipid 
bilayers showed improved enzymatic activity. However, the long-term stability and kinetic 
properties of the immobilized enzymes were not studied in detail. 
Despite its apparent limitations, immobilization based on covalent modifications of the 
protein structure has also been used in the immobilization of microsomal constructs.
Schejbal et al.96 immobilized CYP2C9 baculosomes on magnetic particles to create a CYP-
IMER for drug metabolite analysis coupled with capillary electrophoresis (CE). The 
researchers used used covalent bonding for immobilization, utilizing standard carbodiimide-
based chemistry.84 Kinetic parameters for diclofenac were determined with the IMER-CE-
setup and shown to be in accordance with the literature. However, the IMER exhibited a 
rapid loss of enzymatic activity, which needed to be compensated by fitting the results into 
an exponential decay model.
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Nicoli et al.97 immobilized recombinant human CYP microsomal vesicles on a 
neutravidin-functionalized liquid chromatography (LC) column by labelling the 
microsomes with biotin via dialysis. The constructed IMER was used to conduct on-line 
drug metabolism studies by coupling the system to a mass spectrometer. However, the 
kinetic parameters of the immobilized enzyme were not assessed. Moreover, the reactions 
had to be conducted at room temperature because the immobilized enzyme was not stable 
at elevated temperatures. The immobilization protocol of the microsomes was also rather 
complex and time-consuming, involving two 2h-long dialysis steps used to remove 
interfering substances and unreacted material, which can also compromise enzyme stability
(Figure 3B). Nevertheless, from the standpoint of kinetic determinations, the support-
binding approaches reported by Schejbal et al.96 and Nicoli et al.97 represent the state-of-the 
art in CYP/UGT immobilization in the sense that they are not as prone to diffusional 
restrictions as scaffold-based systems are.
Figure 3. Immobilization approaches for microsomal drug-metabolizing enzymes. A) Human 
liver microsomes entrapped inside poly(ethylene glycol) micropillars. Modified and reprinted from 
ref. 92. © 2013, with permission from Elsevier. B) Schematic of a CYP immobilization procedure 
based on affinity binding of covalently biotinylated microsomes on a neutravidin-functionalized 
monolithic mini-column. Modified and reprinted from ref. 97. © 2008, with permission from 
Elsevier. C) Schematic of a micropatterned lipid membrane used for immobilizing CYP-containing 
microsomes. Modified and reprinted from ref. 95. © 2007, with permission from Elsevier.
2.2.2 Immobilization of soluble CYP enzymes
The earliest attempts at immobilizing membrane proteins involved the immobilization of 
whole-membrane fragments.98 These approaches often suffered from high levels of 
nonspecific binding and instability. Consequently, in contemporary techniques, membrane 
proteins are usually solubilized and reconstituted in detergents or lipids with defined 
characteristics. CYP enzymes can be rendered soluble by deleting the hydrophobic N-
terminus sequence. For soluble CYPs, covalent bonding is more applicable because the 
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different functional groups of the amino acids are more readily available for bonding using 
different chemistries; this is likely why covalent immobilization is the method of choice 
when working with soluble CYPs.99–101 A drawback of using soluble CYPs is that the 
auxiliary proteins must be applied in solution along with the substrate for each reaction, 
which considerably increases operational costs. It is also possible to immobilize the redox 
partners on the same carrier as the CYPs, but the adjustment of spatial relationships and 
stoichiometric ratios of the different proteins might prove challenging. In one example of 
covalent immobilization of recombinant CYPs, Wollenberg et al.99 immobilized soluble
recombinant CYP2C9 using amine-directed coupling to a UV-activated poly(methyl 
methacrylate) (PMMA) surface. Compared to the soluble enzyme, stability was improved 
in the immobilized enzyme. However, the costly cofactor POR needed to be supplied 
alongside the substrate, undermining the economic feasibility of this design.
Cross-linking is not easily implemented for membrane-bound enzymes. Cross-linking 
microsomal vesicles as such would likely result in enzyme inactivation and uncontrollable 
aggregation of microsomes, which would in turn limit substrate diffusion. However, soluble 
bacterial CYP enzymes have been immobilized by cross-linking. Tan et al.102 immobilized 
a soluble bacterial CYP with its redox protein partners by supramolecular complex 
formation, fusing the enzymes to self-assembling protein linkers. The cross-linked enzyme 
formed a reusable, water-insoluble gel.
CYPs can also be immobilized on electrode surfaces. The use of electrodes can obviate 
the need for NADPH and auxiliary proteins since electrons can be accepted directly from 
the electrode surface. This way, CYPs can be used as biosensors by monitoring changes in 
electrical current when exposing the system to different substrates. 
Although technically feasible, immobilization of soluble CYPs is unlikely to meet the 
needs of in vitro drug discovery because of this technique’s poor correlation with in vivo
clearance.103 Because of this, this thesis focuses mainly on methodology applicable to 
membrane-bound enzymes.
2.3 Microfluidic systems in drug metabolism research
The concept of micro total analysis systems (μTAS), enabled by the utilization of 
microfabrication and microfluidics, was first coined in a seminal paper by Andreas Manz 
and colleagues in 1990.104 Since then, microfluidic systems have found use in practically all 
fields of chemistry and biology, ranging from simple point-of-care diagnostic devices105 to 
intricate body-on-a-chip systems106 that emulate human physiology. 
In pharmaceutical sciences, microfluidic systems have gained attention as novel tools 
that could potentially speed up the cumbersome drug development process.107 The 
manipulation of minute volumes within micro- or nanometer-sized channels, results in 
decreased consumption of expensive bioreagents (such as the cofactors of enzymatic 
reactions). Owing to the short distances and high surface-to-volume ratios in microfluidic 
channels, mass and heat transfer occur rapidly, which both facilitate precise control of 
experimental parameters and reduces total analysis time.108,109 One key advantage of 
microfluidic systems, made possible by their small size and the utilization of modern 
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microfabrication processes, is the integration of several functional units (e.g. reaction, 
separation and detection) on one integrated microchip. The implementation of immobilized 
enzyme microreactors in the microscale also benefits from the same advantages. This 
chapter focuses on different aspects of microsystem design, with a focus on miniaturization 
of immobilized enzyme reactors. 
2.3.1 Microfabrication
Microfabrication encompasses all technologies intended to structures at or below the 
micrometer scale. Microfabrication processes were originally developed by the 
semiconductor industry for the creation of integrated circuits in silicon. In recent decades, 
these processes have been also adopted by the microfluidics community. In addition, several
methodologies have been developed solely for purpose of fabricating microfluidic devices.
First-generation microfluidic chips were made from silicon and glass using standardized
photolithography methods initially developed for silicon.110 More recently, polymer 
materials have rapidly replaced glass and silicon in microfluidic applications. This is due to
a multitude of reasons. While silicon was an obvious choice of material for microelectronics 
given its semiconductive properties, it is not as suitable for the manufacturing of 
microfluidic systems for applications in chemistry or life sciences. For example, microchip 
capillary electrophoresis requires high voltages that simply cannot be generated on a 
conductive material. The immense range of polymer materials, on the other hand, represent 
a cornucopia of physico-chemical and mechanical properties so that the most feasible 
material can be chosen based on the specific requirements of each application. Fabrication 
of glass and silicon is costly and typically requires hazardous chemicals and clean room 
facilities,111 whereas polymer fabrication is often a less demanding process. In particular, 
the 1998 introduction of soft lithography-based prototyping of PDMS microstructures by 
George Whitesides’ laboratory112,113 paved the way for the efficient utilization of polymer 
materials. PDMS soft lithography enables replication of silicon microstructures in PDMS 
itself, but also allows the use of PDMS as an intermediate mold for replication of high-
definition microstructures in practically any heat- or light-curable polymer material under
normal laboratory conditions, as will be described later. Given the prevalence of polymers
in microfluidic applications, the remainder of this chapter will focus solely on polymers.
Polymer microfabrication techniques can be divided into two categories: (i) direct 
machining methods, including micromachining and lithography, and (ii) replication 
methods, including embossing and casting. Most thermoplastic materials can be patterned 
with both direct machining and replication methods, whereas elastomer patterning is done 
mostly by casting and thermoset patterning via UV lithography.111 All microfabrication 
techniques have different limitations with respect to feature resolution and accuracy, and 
these must be considered on a case-by-case basis. In general, lithography offers the highest
accuracy and feature resolution, but elastomers casted on master structures defined by 
photolithography can also produce relatively high resolution patterns.112 Casting and 






Photolithography is the process of exposing a photosensitive material to (UV-)light through 
a photomask that defines the patterned shape.114 Photolithography lies at the heart of the 
semiconductor industry, where it is routinely used in the fabrication of common electronic 
components. In this context, photolithography is utilized in the direct processing of silicon, 
whereas in the microfluidics field photolithography is also used as an intermediate step in 
creating high-definition molds for use in polymer replication.111,112 In the photolithographic 
process (Figure 4), the substrate is first coated with a light-sensitive photoresist. Next, the 
photoresist is exposed to UV-light through a photomask selectively exposing some parts of 
the resist, defining the pattern to be fabricated. After exposure, the photoresist is developed 
using a solvent. Depending on the polarity of the resist, either the exposed parts (positive 
resists) or the unexposed parts (negative resists) are dissolved in the developer solution. In 
silicon processing, the underlying silicon layer is then selectively etched before removing 
the photoresist. Many photoresists have rather low viscosity, resulting in very thin layers 
(on the order of a few microns), thereby restricting their use in microfluidic applications 
that require the manipulation of cells, or volumes at the microliter scale. Some photoresists, 
such as the epoxy-based negative tone photoresist SU-8, can be used for the fabrication of 
layers that are hundreds of micrometers in depth, which is why it is widely used in the 
microfluidics field both for the creation of standalone devices115,116 and as a mold for 
replication of high-aspect ratio structures.113,117  
 
Figure 4. Schematic illustrating the soft lithography processing of PDMS negative photoresist. 
The process consists of 1) patterning of the negative photoresist SU-8 through a photomask, 2) 
developing the exposed photoresist, 3) replica casting of PDMS using the SU-8 layer as a master 
structure, and 4) bonding the obtained PDMS layer on a substrate (e.g., glass) to create 
microchannels. 
In all replication methods, structures defined by a master mold are replicated on a polymer 
substrate. The material requirements of the master mold depend on the replication method 
used, but common desirable attributes include high precision of the structures, minimal 







techniques like injection molding,118 where thermoplastics are structured by elevated heat 
and pressure, the structural demands for the mold are more strict, making the mold 
fabrication more expensive and time-consuming. Many replication methods, such as
injection molding and hot embossing,119 also require specialized machinery. Owing to its 
simplicity, casting is often the replication method of choice especially in low-cost 
preliminary prototyping, when new designs are revised on a regular basis. Replication by 
casting is a straightforward process where the liquid polymer mixture is simply poured on 
top of a master mold (typically fabricated from SU-8), cross-linked using heat or UV-light, 
and detached from the mold. The aforementioned PDMS soft lithography process is a 
typical example of such a replication process, and owing to its many beneficial qualities 
(see section 2.3.2), PDMS is by far the most widely used material in casting.120 Because the 
elasticity of PDMS facilitates the detachment of even very rigid polymers from the mold, 
PDMS is the most commonly used negative mold material for replicating the master 
structures on other polymers curable by heat or light.121
2.3.2 Materials
As manufacturing materials, polymers offer a wide-range of physico-chemical as well 
as mechanical properties, and can be classified into three main categories: thermosets, 
thermoplastic materials, and elastomers.111,122 Thermosets, such as the photoresist SU-8, are 
materials that can be cross-linked using heat or radiation, generating a relatively hard and 
inflexible molecular network. This process is irreversible, and the material cannot be 
reshaped after curing. Thermoplastic materials, such as poly(methyl methacrylate) (PMMA) 
show a distinct softening at their glass transition temperature, which permits processing
using replication methods. Thermoplastics do not cure per se, so they can be reshaped by 
reheating. Elastomers, such as PDMS, contain long molecular chains that are physically 
entangled rather than chemically linked. Elastomers characteristically have a low Young’s 
modulus and can return to their original shape after external stress is removed.
The aforementioned simplicity and low cost of PDMS fabrication—along with many
beneficial properties, including optical transparency, high oxygen permeability, and 
inherent cell compatibility—often make PDMS an optimal material, especially for many 
organ-on-a-chip applications. However, PDMS also has several limitations, including
limited solvent tolerance and the tendency to swell upon exposure.123 PDMS rapidly 
becomes hydrophobic as it ages, which often causes unwanted adsorption and absorption of 
hydrophobic molecules on the chip surface and bulk, respectively, altering solute 
concentrations and inducing cross-contamination between repeated experiments.124,125
PDMS surfaces can be rendered hydrophilic by plasma oxidation, but the process is 
reversible and the surface will regain its hydrophobicity with time.113,126 To overcome the 
limitations of PDMS, several alternative polymers have been introduced in the literature, 
including but not limited to PMMA,127 polycarbonate,128 and thiol-enes.129
The surface chemistry of the microreactor plays a key role, especially in covalent 
immobilization. The surface must contain a suitable functional group to facilitate 
immobilization.130 Most polymer materials, such as PDMS131 and PMMA132 are relatively 
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inert, and the suitable chemistry must be introduced in a separate functionalization step, for 
example by using  ionized gas,133 wet chemical treatments132 or UV-induced reactions.134
These steps often involve the optimization of several inter-dependent parameters, including 
processing time and temperature, to ensure replicable results.133
Since their introduction in the early 2010’s,135 off-stoichiometric thiol-enes (OSTE) 
have gained increasing attention in the microfluidics community, owing to their tunable 
physico-chemical and mechanical properties. In general, thiol-enes are a family of 
thermoset polymers made up of two monomers, each containing at least two thiol or allyl 
groups.136 The monomers polymerize via a fast UV-induced click chemistry reaction,137
leading to high monomer conversion with high selectivity. A key feature of OSTEs is the 
ability to easily tune the bulk and surface properties of the polymer by simply changing the 
ratio of the thiol and allyl monomers. The thiol-ene click reaction proceeds through a step-
growth polymerization mechanism, consuming both monomers in equal amounts.137 Using 
off-stoichiometric compositions will thus result in an excess of one functional group on the 
polymer surface as well as in the bulk.138 This feature of the material offers some advantages
for the back-end processing steps of microfluidic systems, such as bonding and surface 
functionalization. Thiol-enes can be fabricated by replica molding,121,135 which makes them 
well suited for fast prototyping purposes. Thiol-enes also lend themselves to 
photolithographic processing with good structural quality.139 As a result, OSTE have been 
successfully applied to a variety of different applications including but not limited to 
microchip electrophoresis,140 cell culturing,141 and microreactors.121,142,143
In terms of functionalization, OSTE surfaces are intrinsically rich in either free allyl or 
thiol groups, both of which lend themselves to straightforward bioconjugation via click 
chemistry reactions.144–146 Since the thiol-ene reaction is photoinitiated, the bioconjugation 
can also be spatially controlled by using a photomask.147 The tunable surface chemistry 
makes OSTE an excellent material for applications where enzyme immobilization is needed, 
as evidenced by numerous recent reports on OSTE-based microreactors.121,142,148,149
In addition to surface functionalization, bonding is often another stumbling block in the 
fabrication of sealed microdevices, including flow-through microreactors.150 OSTE 
microstructures can be sealed easily by using opposite excesses of thiol and allyl monomers 
in the layers to be bonded.135 Instead, most polymer materials lack suitable, reactive surface 
chemistry to facilitate bonding of two polymer layers. Chemically inert thermoplastics are 
typically bonded by thermal fusion bonding or adhesive bonding. Fusion bonding is based 
on heating substrates above their glass transition temperature and pressing the pieces 
together, effectively “melting” the two layers into one.150 The resulting seal is rather strong, 
but the applied heat and pressure may result in simultaneous microchannel deformation. 
Using an intermediate adhesive layer allows for straightforward bonding of practically any 
two materials at low temperatures and pressures.151 However, as it is challenging to apply a 
uniform and thin layer of the adhesive, the bonding often results in clogging of the
channels.150 Owing to its conformity, PDMS can spontaneously seal against itself or any 
other smooth surface, without the need for adhesives or special instrumentation.113 The 
bonding of native PDMS is reversible and cannot withstand high pressures, but irreversible 
seals can be made by treating the surface with plasma prior to bonding. From this 
perspective, the covalent bonding of two OSTE surfaces fabricated using off-stoichiometric 
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monomer ratios is extremely straightforward and can be done without any surface activation 
or adhesives.135 The only caveat of OSTE bonding is that only surfaces with opposite surface 
chemistries can be bonded together, resulting in varying surface properties in the 
microstructures. Novel OSTE compositions (marketed under the name OSTE+) containing
an additional epoxy component can be bonded using a second heat-initiated thiol-epoxide 
polymerization step.152 Another way of circumventing the need for surfaces with opposite 
chemistries is omitting the photoinitiator from the monomer mixture. In the presence of a 
photoinitiator, polymerization results in fully polymerized and inert surfaces.153 Without the 
initiator, reactive functional groups remain on the surface, allowing strong bonding of the 
layers, even if they are of the same composition.140,154 Under these circumstances, bonding 
strength is mainly defined by the bulk polymer rigidity.154
From a material standpoint, the flow-through microreactors used in drug metabolism 
studies are not the most demanding application, since high pressures are not needed. 
However, some special characteristics must be considered when selecting a suitable 
fabrication material. Solvent compatibility is not an issue, since drug metabolism assays are 
conducted in aqueous buffer solutions. However, solvents may be needed for surface 
functionalization before enzyme immobilization, depending on the chemistry involved.
Operational temperatures are also rather low, but the material should be able to withstand
physiological temperatures (i.e., 37 °C). Attention should, however, be paid to a well-known 
issue common to most polymer materials: the impacts of non-crosslinked monomers or
additives possibly leaching out of the bulk polymer.155,156 These leaching moieties can
interfere with the enzymatic reactions of interest, and their effects should be carefully 
examined to ascertain material inertness in the context of drug metabolism applications.
2.3.3 Design considerations for immobilized enzyme microreactors
As discussed in Chapter 2.2, enzyme immobilization based on solid support binding is likely 
the most feasible approach for applications involving kinetic characterization to eliminate 
the diffusional constraints in enzyme kinetic determinations (an inherent challenge with 
immobilization strategies based on entrapment). In addition to the chemistry used for 
enzyme immobilization, the amount of immobilized enzyme depends largely on the total 
available surface area of the reactor. When immobilizing enzymes inside microreactors, the 
reactor walls rarely provide a high enough surface-to-volume ratio for producing detectable 
concentrations of metabolites. Various techniques can be utilized to maximize the catalytic 
surface area of an enzyme reactor, namely packing the reactor with microparticles (Figure 
5A),96,157 polymerizing a porous monolith structure inside the reactor using heat- or UV-
light-curable polymers (Figure 5B),142,158 or fabricating micropillar arrays as solid supports 
(Figure 5C).121,159 The pros and cons of these different approaches are discussed in more 
detail below.
34
Figure 5. Microreactor packing strategies. A) Microreactor comprising a plug of magnetic 
beads maintained between two external magnets. Reproduced from ref. 160 with permission from 
The Royal Society of Chemistry. B) SEM micrographs of the internal structure of monolithic 
structures with different polymeric compositions. Reprinted with permission from ref. 158. © 2002
American Chemical Society. C) Microfabricated silicon micropillar structures. Reprinted with 
permission from ref. 161. © 2002 IEEE.
A wide range of microparticles are commercially available, featuring different surface 
chemistries made from various polymers or inorganic materials. Particle packing is 
relatively straightforward, as the particles can be introduced into the microreactor simply 
by injection. To prevent particle leakage, a frit structure is usually included in the reactor 
design.162 When using magnetic particles, external magnets can also be utilized to hold the 
particles in place.160 When using porous particles, mass transport can become an issue as it 
is restricted by molecular diffusion.163,164 Tight packing of microparticles can also generate 
significant back pressure within the system, compromising the sealing of the microdevice.
A porous monolith is usually produced from a single mass of polymeric or inorganic 
material that is cross-linked in situ inside a reactor space.163 The monolithic material 
comprises a highly interconnected network of pores facilitating mass transfer by convection. 
In addition to efficient mass transfer, advantages of monolithic structures over particles 
include lower back pressures and more stable structures with no risk of solid phase 
leakage.163,164 Depending on the starting material, polymerization can be induced by either 
heat or UV light. When using UV light, monolith formation inside the reactor can be 
spatially defined by photomasking if the chip material is UV-transparent. Controlling the 
size and uniformity of the monolith pores and total surface area can be challenging and 
requires extensive process optimization. Moreover, the porous monolith may introduce 
diffusional constraints in the same way that scaffold-based immobilization does.
The main advantage of microfabricated micropillars as a solid support is their highly 
reproducible manufacturing and high degree of design freedom to avoid diffusional 
constraints. Compared to porous monoliths, the total surface area of micropillar arrays can 
be kept constant much more easily. This can be of great importance if the amount of 
immobilized enzyme needs to be precisely controlled and quantitated, as is the case when 
determining pharmacokinetic constants. Furthermore, compared to a reactor packed with 
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particles, the perfectly ordered conformation of the pillar array also makes the mass transfer 
and fluid dynamics in the channel more predictable. Additionally, since the micropillars can 
be patterned simultaneously with the channel network, no post-processing steps (such as 
particle packing) are needed.121
In addition to the actual microreactor, several auxiliary elements are needed to create a
complete analytical setup. Most relevant ones in the microreactor context include flow 
actuators and detector elements. These additional elements can either be integrated onto the 
microchip or used as external pieces of equipment. Actuation and detection are discussed in 
more detail below, as examples of IMER design considerations to evaluate.
In IMERs, reaction time is defined by the flow rate inside the reactor. To enable the 
accurate determination of enzyme kinetics, the flow rate must be controlled with high 
accuracy. The most common modes of actuation in microfluidics are electro-osmotic flow 
(EOF) and pressure-driven flow.165 EOF occurs when an electric field is applied across a 
microchannel. It is caused by an electric double layer forming at the interface of the channel 
and the electrolyte solution that fills the channel. When an electric potential is applied, this 
mobile layer of ions will induce a bulk flow of solute inside the channel.166 EOF is a 
relatively easy way to implement flow actuation, and lends itself to automation via a
programmable voltage source. The resulting flow also has a very uniform velocity 
distribution across the channel cross-section, which is beneficial for certain analytical 
applications, such as microchip electrophoresis.167 Because EOF is induced by the 
interactions between the electrolyte and the channel surface, it is highly dependent on the 
channel surface chemistry.166,167 Electro-osmotic pumping is rarely used in IMER 
applications because enzyme immobilization almost always involves some chemical 
manipulation of the reactor surface, which could lead to unpredictable changes in EOF 
velocities. By far the most common actuation method for microfluidic systems is pressure-
driven flow.168 The pressure can be generated either by micropumps integrated on-chip,169
or by external devices, such as syringe pumps or pneumatic pressure generators. Integrated 
pressure sources offer minimal dead volumes170 and integrated fabrication, though at the 
cost of complexity and inflexibility of the chip design. Off-chip sources provide a simple, 
universal method of actuation that is compatible with almost any microfluidic device. The 
caveat of external actuation is the fluidic coupling of the pressure source to the device,
which often results in vastly increased dead volumes.
Many chemical reactions need elevated temperatures to reach a sufficient reaction rate, 
while at the same time many enzymes are easily denatured by elevated temperatures. In 
particular, CYPs are very sensitive to temperature changes and have a very narrow optimal 
temperature range (near 37 °C),171 placing demands for efficient and accurate temperature 
control. The simplest way to implement microreactor heating is to place the whole setup 
inside an incubator. However, the spatiotemporal control of heating can be improved by 
using integrated heating elements with an automated feedback control unit.
The choice of analyte detection method depends primarily on the analytical task at hand.
In drug development, pro-fluorescent or pro-luminescent probe substrates are often used in
preliminary screening applications because they enable the use of simple workflows 
compatible with high-throughput well plate protocols.31 However, due to insufficient 
enzyme selectivity, these probes do not allow the use of HLM and are instead used mainly 
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for DDI screening with recombinant enzymes. For most other analytical applications in in
vitro metabolism studies, liquid chromatography–tandem mass spectrometry (LC-MS/MS) 
is the industry gold standard due to its universality. The most common detection methods
used in microfluidic applications include optical methods based on absorbance or 
fluorescence, electrochemical detection (EC), and mass spectrometric (MS) analysis. Again, 
these can be performed either as an integrated unit operation on-chip or by using 
conventional analytical platforms such as well-plate readers or liquid chromatographs off-
chip. In general, miniaturization raises challenges for analyte detection since the number of 
molecules to detect naturally decreases with smaller volumes. Absorbance detection is 
particularly affected by miniaturization due to the direct proportionality of the analyte signal 
to the length of the detection pathway, which is intrinsically small in microfluidic 
systems.172 Consequently, electrochemical detection and fluorescence detection with high-
power excitation sources (i.e. lasers) are more often used in microfluidic systems. EC is a 
good fit for microfluidic analysis as detection sensitivity is unaffected by miniaturization. 
Moreover, miniaturization often results in lower background signals and thus improved
signal-to-noise ratios.173 EC electrodes can be easily implemented on-chip via established 
microfabrication protocols.174 Fluorescence detection can offer high sensitivity and can be 
used for in situ detection as well, as long as an optically transparent chip material (such as 
PDMS or OSTE) is used. However, many analytes—including many metabolites—are not 
intrinsically electroactive or fluorescent, nor are they chemically suitable for conjugation 
with electroactive or fluorescent moieties. Of all detection methods, MS offers the best 
sensitivity and selectivity, while also enabling the identification of unknown compounds in
metabolic profiling. Consequently, mass spectrometric detection coupled with LC 
separation is clearly the most commonly used analysis method in microreactor research.
Microfluidic systems have been successfully coupled with MS analysis using several 
approaches,175,176 but the integration of on-chip ion sources or chip-to-MS interfacing in 
general requires special expertise and is by no means a routine task. In practice, the 
integration of detection methods in drug analysis applications is further complicated by the 
fact that substrates and metabolites are usually highly chemically similar molecules and can 
interfere with each other’s detection. In addition, other assay constituents, such as enzyme 
cofactors present in high concentrations, are often fluorescent and interfere with analyte 
detection via fluorescence. Therefore, a separation step (for example by capillary 
electrophoresis) is often needed before analyte detection, unless pro-fluorescent probe 
compounds are used. Given these complications, sample fractions are usually collected out 
of the microreactor and analyzed off-chip. 
2.3.4 Current state of the art in microfluidic drug metabolism studies
Amidst a vast amount of literature on microreactors, those using immobilized CYP or UGT 
enzymes are under-represented. This is presumably in large part because of the lack of 
suitable immobilization methods for membrane-bound enzymes. The literature to-date is
two-fold, including studies focused on the implementation of enzyme immobilization and 







Figure 6. Integrated microfluidic systems comprising microreactors with immobilized HLM. A) 
Integrated microfluidic system containing immobilized HLM interconnected to an on-chip SPE-
column for pretreatment prior to analysis with ESI-MS, with simultaneous cell toxicity assay with 
on-chip cultured HepG2 cells. Reproduced from ref. 74 with permission from The Royal Society of 
Chemistry. B) A microfluidic chip with sol-gel entrapped HLM interfaced with a cell culture 
chamber and microchip capillary electrophoresis for metabolite analysis. Reproduced from ref. 75 
with permission from The Royal Society of Chemistry. C) Schematic drawing of an integrated 
microfluidic system comprising immobilized HLM for drug metabolism, cell cultivation modules 
for toxicity assay and sample pretreatment column prior to analysis with ESI-Q-TOF MS 
Reproduced from ref. 93 with permission from The Royal Society of Chemistry. D) A schematic 
and a photograph of a modular microfluidic system for the study of coupled phase I–phase II 
metabolic reactions. Reprinted with permission from ref. 157. © 2014 American Chemical Society. 
Previous studies on microreactors comprising drug-metabolizing enzymes focus mainly on 
CYP metabolism. In the case of UGTs, studies are limited to only a handful of proof-of-
concept studies implemented in conventional capillary-based systems, which do not lend 
themselves to integration in the same manner as microfluidic systems.177–179 The drawback 
of most reported CYP microreactors to-date is that they settle for a brief demonstration of 
metabolite production on-chip with a modest increase in enzyme stability,89,97,99 without 
properly characterizing enzyme function or challenging the setup with enzyme kinetic 
experiments. On the other hand, when kinetic parameters have been studied in more detail, 
issues with  diffusion-limited kinetics caused by immobilization arise, indicating that there 
is still room for improvement in the immobilization of membrane-bound enzymes.92 
Besides reports on the implementation of IMERs, a few proof-of-concept studies have 
presented impressive integration of HLM microreactors with additional functional units, 
such as a cell-based toxicity assays or integrated separation and detection units (Figure 
6).74,75,93,157 Kampe et al.157 demonstrated that sequential phase I–phase II metabolism in a 
compartmentalized microreactor system can yield drug metabolites that are not obtained in 
a one-pot suspension assay. The integration of a microreactor module with a cytotoxicity 
assay and online metabolite analysis with either electrophoresis75 or MS74,93 have also been 
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reported, and such setups have the potential to significantly streamline preclinical drug 
research. These studies highlight the fact that microfluidics is a widely enabling technique 
with a view to drug metabolism research. However, all of these studies emphasize only the 
technical feasibility of integrating the different functional parts. Consequently, the 
microreactor segments are somewhat vaguely characterized, and little data on enzyme 
stability or kinetic characterization is presented. This makes the use of these platforms for 
in-depth investigation of drug metabolism rather premature.
As is the case with most other biological microfluidic models, and also the prevailing in 
vitro techniques for drug metabolism studies, the impact of oxygen is a completely 
neglected dimension in microreactor development. All of the previously reported IMER 
platforms were operated under ambient air, with no capabilities to control oxygen levels 
inside the reactor. Recently, OSTE polymers were reported to have an inherent oxygen 
scavenging capability.180—a truly unique material property linked with the oxidation of the 
thioether-linkages in the polymer backbone. The exploitation of material-induced oxygen-
scavenging could open new possibilities for implementing metabolism experiments in 
normoxic conditions using rather simple microchip designs, although for wider exploitation, 
the mechanistic basis of oxygen scavenging should be examined in greater detail. In 
conclusion, the current state of the art in microfluidic drug metabolism studies mostly 
emphasizes the integration of microreactors with other functional units. The microreactor 
segments themselves remain rather poorly characterized with little data on enzyme stability 
or kinetics, which undermines their applicability for in-depth investigation of drug 
metabolism. Consequently, there is a need for a well-characterized, robust, and easily 
integrated microreactor platform for drug metabolism studies that does not compromise 
enzyme stability or kinetic properties. 
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3 Aims of the study
The overall aim of this thesis work was to investigate the applicability of microreactor 
technology in the study of drug metabolism. To this end, the main technical aim of this 
thesis was to transfer in vitro drug metabolism assays into flow-through conditions by 
establishing a microfluidic reactor platform incorporating major human drug-metabolizing 
enzymes. To achieve this goal, both the manufacturing method and the subsequent 
functionalization and enzyme immobilization steps were carefully examined. The specific 
aims of the work, and the particular publication (I-III) in which these aims are addressed, 
were as follows:
The identification of a suitable fabrication material and surface functionalization 
strategy for immobilized enzyme reactors (I)
Development and characterization of an immobilization method for membrane-
bound enzymes that does not compromise their activity or kinetic properties (I)
Validation of the developed methodology in terms of enzyme stability and 
kinetic parameters of CYPs (I) and UGTs (II)
Identification and elimination of possible material interactions that could affect
metabolic reactions (II, III)
Understanding the mechanistic basis of material-induced oxygen-scavenging of 
OSTE (III) and utilizing this phenomenon to control the oxygen partial pressure 
in microfluidic channels (III)




This section briefly describes the most relevant chemicals and materials, instrumentation, 
processes and analytical methods used in this study. More detailed descriptions are found 
in the respective original publications (I-III).
4.1 Chemicals and materials
Chemicals and commercial materials used in the study are listed in Table 2 and Table 3,
respectively. All chemicals were of analytical grade unless otherwise noted. Chemicals and 
materials used in the fabrication of microchips are listed in Table 4.























rhodamine B sulfonyl) (ammonium 
salt) (Lissamine Rhodamine B-DOPE)






Avanti Polar Lipids, 
Alabaster, AL
Reagent I
2-propanol Sigma-Aldrich, Steinheim, 
Germany
Solvent I-III
3’-amino-3’-deoxythymidine (AMT) Toronto Research 
Chemicals, Ontario, Canada
Metabolite III
5,5-dithio-bis-(2-nitrobenzoic acid) Sigma-Aldrich, Steinheim, 
Germany
Reagent III





















Acetonitrile Sigma-Aldrich, Steinheim, 
Germany
Solvent II
β-nicotinamide adenine dinucleotide 





Biotin-PEG4-alkyne Sigma-Aldrich, Steinheim, 
Germany
Reagent I-III
Chloroform Sigma-Aldrich, Steinheim, 
Germany
Solvent I-III





Dimethyl sulfoxide Sigma-Aldrich, Steinheim, 
Germany
Solvent I-III











Magnesium chloride hexahydrate Sigma-Aldrich, Steinheim, 
Germany
Reagent I-III
Methanol Sigma-Aldrich, Steinheim, 
Germany
Solvent I-III










Perchloric acid Riedel-de Haën, Seelze, 
Germany
Reagent I-II
Phosphate buffered saline Sigma-Aldrich, Steinheim, 
Germany
Reagent I-III
Streptavidin (Alexa Fluor® 488 
conjugate)













Water (Milli-Q) Millipore, Molsheim, France Solvent I-III











Table 3. Commercially available materials and products used in the study.








Dynabeads® M-280 Life Technologies, Oslo, 
Norway
Magnetic beads I
Human liver microsomes 
(HLM), 20 donor pool
Corning, Wiesbaden, 
Germany
Contains all endogenous 
CYP/UGT isoforms
I-III
P450-Glo™  assay Promega, Madison, WI CYP luminescence assay I
Pierce™ BCA Protein 
Assay Kit





Pyro Science, Aachen, 
Germany
Oxygen sensor indicator III















Saint Louis, MO or Bruno 
Bock, Marscacht, Germany
I-III
Sylgard 184 base elastomer and curing agent Down Corning Corporation,
Midland, MI
I-III
SU-8 developer mr-Dev 600 Micro resist technology, Berlin, 
Germany
I-III




Commercial instruments used in the study are listed in Table 5, with notes explaining their
specific use. In addition to the listed instruments, some standard equipment and devices 
built in-house were also used.
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Curing of thiol-enes I-III
MA-6 mask aligner Sûss Microtec, Garching, 
Germany
SU-8 exposure I-III
miniFactory 3 3D printer miniFactory, Seinäjoki, 
Finland
Chip holder fabrication I-III
OAI LS 30 NUV collimated 
light source
OAI, San Jose, CA SU-8 exposure III
Plasmalab 80+ Oxford instruments, 
Bristol, UK
Chemical vapor deposition I-II
Metabolite analysis
ACQUITY UPLC™ Liquid 
chromatograph
Waters, Milford, MA Sample separation II-III
Varioskan™ Flash 
multimode reader













Xevo Q-S triple quadrupole 
mass spectrometer
Waters, Manchester, UK Mass analysis II-III
Material characterization
8101e OxySense® Oxygen 
Transmission Rate 
Analyzer




















Moticam 3500 color CCD 
camera
Motic, Xiamen, China Image capture I
Piccolo2 oxygen meter Pyro Science, Aachen, 
Germany
Oxygen measurements III
PicoScope 2203 AD 
converter
Pico Technology, St. 
Neots, UK
Fluorescence quantitation I
Surface tension meter KSV Instruments Ltd., 
Helsinki, Finland








Quanta™ 250 FEG 
scanning electron 
microscope 
FEI, Hillsboro, OR Microstructure 
visualization 
I-III 
Zeiss AxioScope A1 upright 
epifluorescence microscope 










Zetasizer Nano ZS Malvern, Worcestershire, 
UK 




11 Elite Syringe pump Harvard Apparatus, 
Holliston, MA 
Flow actuation I-III 
CMA 470 refrigerated 
microfraction collector 
CMA Microdialysis AB, 
Kista, Sweden 
Fraction collection II-III 
4.3 Microfabrication and chip designs 
The microreactors developed in this work were fabricated based on replica molding of off-
stoichiometric thiol-enes. The fabrication process comprised four steps: 1) fabrication of an 
SU-8 master; 2) casting of a poly(dimethyl siloxane) (PDMS) mold using the SU-8 master 
as a template; 3) UV replica molding of the thiol-ene microchannel and cover layer using 
the PDMS mold; and 4) bonding of the two thiol-ene layers using lamination and UV light. 
A schematic overview of the fabrication process is illustrated in Figure 7.  
 
Figure 7. Schematic of the thiol-ene chip fabrication protocol. 
The microfabrication of the SU-8 masters using UV photolithography was done either in a 
cleanroom environment (Micronova, Espoo, Finland, Publications I-II) or in a regular wet 
chemistry laboratory setting (Faculty of Pharmacy, University of Helsinki, Finland, 
Publication III). Detailed fabrication parameters can be found in the respective original 
PDMS soft lithography,








papers and supporting materials. Briefly, SU-100 negative photoresist was spin coated on a 
4 inch silicon wafer substrate and soft baked on a hotplate to yield a 200-μm-thick layer of 
SU-8. After UV exposure through a photomask, the master was developed by immersion in 
mr-Dev-600 developer.
The PDMS molds were prepared by mixing the Sylgard 184 base elastomer and the 
curing agent in a 10:1 ratio (w/w). After degassing in a vacuum for 30 min, the mixture was 
casted onto the SU-8 master and cured by heat (70 °C for 3 h or 65 °C overnight).
The thiol-ene layers were prepared by mixing trimethylolpropane tri(3-
mercaptopropionate) (i.e., “trithiol”) or pentaerythritol tetrakis(3-mercaptopropionate (i.e., 
“tetrathiol”) and 1,3,5-Triallyl-1,3,5-triazine-2,4,6(1H,3H,5H)-trione (i.e., “triallyl”)
monomers (Figure 8) in a defined molar ratio with respect to free functional groups. After 
pouring the monomer mixture onto the PDMS mold and degassing in a vacuum for 
approximately 5 min, the thiol-ene was cured under UV light for 5 min (Dymax EC5000 
flood exposure lamp, nominal power 225 mW/cm2). The cured microchannel and lid layers 
were heated above their glass transition temperature (ca. 70 °C), laminated together, and
exposed to UV light for an additional 2 min. 
Figure 8. Chemical structures of the thiol and allyl monomers used for fabricating thiol-ene 
microreactors.
The chip designs utilized in this thesis are illustrated in Figure 9. Design 1 involved a single-
channel microreactor featuring a dense micropillar array for maximizing the surface area 
available for enzyme immobilization. Design 2 was an integrated design with the 
microreactor compartment interfaced with six serially connected micropillar channels 
responsible for scavenging oxygen out of the feed solution. The micropillar array consisted 
of an array of approximately 14,400 micropillars (Ø 50 μm) in a hexagonal lattice with an








Figure 9. Schematic drawings of the chip designs used in this work: 1) single-channel 
microreactor with a micropillar array (publications I and II), and 2) integrated design with the 
microreactor (highlighted in yellow) interfaced with six serially-connected micropillar arrays for 
oxygen scavenging (highlighted in blue) (publication III). The inlay shows the detailed dimensions 
of the micropillar array (in μm), and a SEM image of the pillar array. 
4.4 Immobilization of human liver microsomes 
The method for immobilizing membrane-bound enzymes on solid supports developed in 
this thesis comprised of two steps: 1) biotinylation of membrane constructs comprising the 
enzymes (i.e. liver microsomes) via spontaneous fusion with biotin-tagged fusogenic 
liposomes, and 2) immobilization of the biotinylated membrane constructs on avidin-
functionalized microreactors made of off-stoichiometric thiol-enes.  
4.4.1 Biotinylation of lipid membranes using fusogenic liposomes 
The lipid composition of the biotinylated fusogenic liposomes (b-FL) used in this study was 
modified from previous work.181,182 The b-FL were prepared by mixing chloroform stock 
solutions of 1,2-dioleoyl-sn-glycero-3-phophoethanolamine (DOPE), 1,2-dioleoyl-3-
trimethylammonium-propane (DOTAP), biotin-cap-DOPE (all 10 mg/mL), and lissamine 
rhodamine B-DOPE (1 mg/mL) in a lipid mass ratio of 1:1:0.1:0.05, respectively. After the 






vacuum conditions for an additional 2 h to remove any solvent residues. Next, the dry lipid 
film was re-solvated in PBS to yield a total lipid content of 2 mg/mL and vortexed for 1 h 
at room temperature. The resulting multilamellar liposomes were passed through a 
polycarbonate membrane (pore size = 100 nm) 51 times to yield large unilamellar vesicles 
(average size 220 ± 25 nm, n=4 batches). Finally, the b-FL (2 mg/mL) and HLM (20 mg/mL 
total protein) stock solutions were mixed in equal volumes and incubated at 37 °C for 15 
min to yield biotinylated HLM (b-HLM). A schematic describing the biotinylation process 
is presented in Figure 10. 
 
Figure 10. A schematic describing the biotinylation of human liver microsomes using biotin-
tagged fusogenic liposomes. Abbreviations: b-FL, biotinylated fusogenic liposome; HLM, human 
liver microsome; b-HLM, biotinylated human liver microsome. Adapted with permission from ref. 
183. © 2019 John Wiley and Sons. 
4.4.2 Microchip functionalization with avidin and enzyme immobilization 
To enable the immobilization of biotinylated HLM inside the microreactor with biotin-
avidin chemistry, the microreactor surface was functionalized with streptavidin (Figure 11). 
First, the reactor was filled with biotin-PEG4-alkyne (0.1 mM in ethylene glycol with 1% 
Irgacure® TPO-L as the photoinitiator) and exposed to UV light for 1 min (λ = 365 nm, 
LED, nominal intensity 14 mW/cm2). After rinsing with both methanol and water (≥ 5mL 
each), the channel was filled with 0.5 μg/mL streptavidin (in PBS), incubated at room 
temperature for 30–45 min and rinsed with ≥ 5 mL PBS. Finally, the reactor was filled with 









the chips were left to incubate at 4 °C overnight. Before use, the microreactor was rinsed 
with ≥ 5mL of the run buffer.  
 
Figure 11. A schematic describing the microreactor functionalization and enzyme 
immobilization protocols.  
Streptavidin-functionalized magnetic beads were also used as the immobilization matrix 
when validating and optimizing the immobilization protocol. Before use, required amount 
of the superparamagnetic beads pre-functionalized with streptavidin (10 mg/mL, particle 
diameter 2.8 μm) were pretreated according to the supplier’s protocol. Next, the beads were 
divided into 25 μL aliquots (0.25 mg of beads) and the supernatant was discarded with the 
help of an external neodymium magnet. The b-HLM (15 μL) was immediately added onto 
the beads and the suspension was incubated on a tilt rotator for 30 min at room temperature. 
Next, the supernatant was discarded and the beads were washed 4–5 times with 50 μL PBS. 
Beads were stored in 50 μL of PBS at 4 °C until use. To serve as a negative control, the 
beads were also functionalized with biotinylated DOPE or DPPE lipids, followed by native 
HLM. 
4.5 Implementation of flow-through assays 
The feed solution was fed through the microreactor with an external syringe pump. The 
reaction time of the flow-through enzyme assays was adjusted by controlling the linear flow 
rate of the feed solution. Metabolites were quantified by collecting 50 μL fractions of the 
output solution either manually or with the help of an automated refrigerated fraction 





















the feed solution. When needed, substrate concentration gradients were created using two 
interconnected syringe pumps (Figure 12). The chips were heated to physiological 
temperature (37 °C) by placing an aluminum heating element under the reactor. The 
temperature on top of the reactor was monitored with a thermocouple and set to 35 °C using 
a proportional–integral–derivative (PID) controller connected to the circuit. Based on an 
earlier study,184 the temperature on top of the channel was assumed to reflect the temperature 
inside the channel to within 2 °C.  
 
Figure 12. Schematic view of the implementation of flow-through assays. 
4.6 Model reactions 
To evaluate if the immobilization of b-HLM affects CYP or UGT metabolism, the kinetic 
constants obtained with immobilized enzyme were compared with reference assays 
performed with non-immobilized HLM in test tubes. The model reactions and assay 
conditions used for studying CYP and UGT metabolism are summarized in Table 6 and 








Table 6. A summary of CYP model activities and assay conditions used in the study. When 
studying the effect of immobilization on the kinetic parameters of selected model reactions, b-
HLM was immobilized on streptavidin-coated magnetic particles.
CYP2A6 CYP2C9 CYP2D6 CYP3A4
Substrate Coumarin Luciferin-H Luciferin-ME EGE Luciferin-IPA










Buffer Tris (0.1 M, pH 7.5) 
+ 3.3 mM MgCl2
Potassium phosphate (0.1 M, pH 7.4)
HLM (total protein) 0.4 mg/mL 0.4 mg/mL 0.4 mg/mL 0.2 mg/mL
Incubation time 15 min 30 min 30 min 10 min
Stop reagent 4 M perchloric acid 
(10 μL)
Luciferin detection reactant (100 μL)
Detection Fluorescence
Ex 325 nm/em 470 
nm
Luminescence
Table 7. A summary of UGT model activities and assay conditions used in the study. When 
studying the effect of immobilization on the kinetic parameters of selected model reactions, b-
HLM was immobilized inside thiol-ene microreactors.
UGT, various isoforms UGT2B7
Substrate 8-hydroxyquinoline Zidovudine





Metabolite 8-hydroxyquinoline glucuronide Zidovudine glucuronide
Buffer Tris (0.1 M, pH 7.5) + 5 mM MgCl2
HLM (total protein) 0.2 mg/mL 0.1 mg/mL
Incubation time 10 min 30 min
Stop reagent 4 M perchloric acid (10 μL)
Detection Fluorescence
Ex 245 nm/em 475 nm
LC-MS
Control incubations with non-immobilized HLM were conducted in Eppendorf tubes at 
37 °C in a total volume of 100 μL. Either NADPH (for CYP enzymes) or UDPGA (for UGT 
enzymes) was used as a cofactor at a concentration of 1 mM. The incubation buffer, the 
amount of HLM, and the incubation time were adjusted enzyme-specifically. Prior to 
initiating the reaction with the addition of the co-substrate, the HLM and the substrate were 
mixed and preincubated at 37 °C for 5 min. If alamethicin was used in the UGT incubations, 
the HLM was incubated with alamethicin at 4 °C for 30 min prior to the 5 min preincubation 
at 37 °C. The reactions were stopped by the addition of 10 μL of ice-cold 4 M perchloric 
acid, after which the samples were kept on ice for 20 min, centrifuged at 16 000 g for 
10 min, and the supernatants were transferred for analysis. Assays conducted using the 
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commercial luminescent CYP probes were stopped by the addition of the Luciferin 
detection reagent (100 μL) and incubated at room temperature for 20 min prior to analysis. 
4.7 Analytical methods
Fluorescence (umbelliferone and 8-hydroxyquinoline glucuronide) and luminescence 
(luciferin substrates) detection of drug metabolites was carried out on a Varioskan Flash or 
a Varioskan LUX multimode microplate reader. Zidovudine-glucuronide and 3’-amino-3’-
deoxythymidine (AMT) samples were analyzed with liquid chromatography-electrospray 
ionization-tandem mass spectrometry (LC-ESI-MS/MS). A Waters Acquity UPLC BEH C-
18 reverse-phase column was used for chromatographic separations. Analytes were detected 
in negative polarity mode using multiple reaction monitoring.  Detailed method parameters 
are outlined in Publications II and III.
4.8 Material characterization
The mechanical and physico-chemical properties of OSTE were characterized in detail 
using the methods described in this section. The structural quality of the microfabricated 
structures was evaluated using scanning electron microscopy (SEM). The success of 
biofunctionalization of thiol-ene surfaces was monitored using both fluorescence 
microscopy and water contact angle (WCA) measurements. The oxygen scavenging 
properties of thiol-ene polymers and monomers were characterized optically using an 
oxygen-sensitive fluorescent dye. To further characterize material properties affecting 
oxygen diffusion, glass transition temperatures and oxygen permeation of selected thiol-ene 
compositions were determined. 
4.8.1 Structural fidelity
The structural fidelity of the microstructures was assessed by scanning electron microscopy. 
Samples were attached onto the sample stage with carbon-coated double-sided tape and 
sputtered with platinum for 25 seconds (30 mA), yielding a 5-nm-thick coating. 
4.8.2 Glass transition temperature
Glass transition values for thiol-ene samples were determined by differential scanning 
calorimetry. The analysis method was comprised of three steps: 1) cooling the sample 
to -35 °C; 2) a 3-min isothermal sequence; and 3) heating the sample from -35 °C to 100 °C 
at a rate of 20 °C/min using nitrogen as a purge gas. Glass transition temperatures were 
determined using STARe software. 
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4.8.3 Oxygen permeability
To determine the oxygen permeability of different thiol-ene compositions, thin polymer 
membranes were fabricated by applying a small amount of uncured thiol-ene monomer 
mixture on a PDMS-coated glass plate, laminating this with another glass plate and curing 
under UV light for 5 min. The glass slides were separated by pieces of double-sided tape, 
resulting in a membrane thickness of 100-200 μm. Membrane thickness was measured 
separately for each sample before the permeability measurement. The oxygen permeability 
of the samples was determined from two replicate samples using an 8101e OxySense® 
oxygen transmission rate analyzer equipped with a coulometric detector.
4.8.4 Wettability
The wetting properties of OSTE surfaces after different functionalization steps were 
characterized using the sessile water drop contact angle method.185 To determine the water 
contact angle (WCA), three drops of Milli-Q water were placed randomly over the OSTE
surfaces and the contact angle was recorded with an optical contact angle meter and 
analyzed using Attension Theta software (Version 4.1.0).
4.8.5 Streptavidin binding and enzyme immobilization
The binding of streptavidin on biotin-functionalized thiol-ene surfaces and the 
immobilization efficiency of b-HLM vesicles on streptavidin-coated thiol-ene 
microchannels was monitored on a Zeiss AxioScope A1 upright epifluorescence microscope
equipped with a Plan-Neofluar 20×/0.4 Corr objective and a HAL100 halogen lamp (100W). 
The fluorescence signals of Atto 488-labelled streptavidin (ex 488/em 500–700 nm) and 
lissamine rhodamine B (ex 546±6 nm, em 575–640 nm) were monitored using a Moticam
3500 color CCD camera or quantified using a Hamamatsu R5929 photomultiplier tube 
equipped with a signal amplifier module and a PicoScope 2203 analog-to-digital (AD)
converter.
4.8.6 Material inertness
The amount of thiol monomers leaching out of the cured OSTE microreactors (fabricated 
with 25% molar excess of tetrathiols) was quantified by titration using Ellman’s reagent 
(5,5′-Dithiobis[2-nitrobenzoic acid], DNTB).186 First, the free surface thiols were 
eliminated by incubating a 1 mM DNTB solution inside the channel for 30 min. Next, fresh 
DNTB solution was incubated inside the channel for different periods of time (10, 20 and 
30 min) followed by the quantitation of thiols based on the UV absorbance of the reaction 
product, 2-nitro-5-thiobenzoate (TNB) (412 nm). For thiol quantitation, a molar extinction 
coefficient of ε = 14 150 /M cm was assumed for TNB.187
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4.8.7 Oxygen scavenging
Oxygen levels inside thiol-ene microchannels were monitored using a fiber-optic oxygen 
meter combined with nanoparticles functionalized with a fluorescent indicator dye. This
measurement is based on the oxygen-sensitivity of the fluorescence lifetime of the dye. The 
nanoparticles were dispersed in de-ionized water at a concentration of 1 mg/mL and the 
fluorescence signal was measured through the optically transparent thiol-ene top layer. The 
meter was calibrated with solutions containing 100% and 0% dissolved oxygen. The 100% 
calibration solution was prepared by repeatedly vortexing a small amount of the 
nanoparticle solution, opening the tube cap in between vortexes. The 0% solution was 
prepared by combining 0.1 mg/mL glucose oxidase and 10 mg/mL glucose in to a small 
aliquot of nanoprobe solution and incubating the sample at room temperature for 10 min.
The effect of polymer composition and different pre-treatments of OSTE on its oxygen 
scavenging properties were investigated using an array of rectangular OSTE microchannels 
(2×30×0.2 mm) bonded on top of a glass substrate. The channels (n=4–8 per treatment 
group) were filled with the nanoprobe solution and the inlets were sealed with Parafilm to 
prevent evaporation. At each time point, five measurements were taken along each 
channel’s length. Oxygen scavenging under flow conditions was studied by connecting 
thiol-ene microchannels to a syringe pump filled with the nanoprobe suspension. All
measurements were performed at 37 °C, and the temperature was maintained using an
aluminum heating block, as with the microreactors.
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5 Results and discussion 
5.1 Conceptualization
This chapter briefly summarizes the rationale behind the choices made in this study, with
respect to microreactor design, materials, and experimental protocols.
With a view to kinetic studies, immobilization approaches based on support binding 
were mainly considered because they are less prone to diffusion-limited kinetics, as 
discussed in Chapter 2.2. Micropillars were chosen as the solid support for enzyme 
immobilization because of two main advantages: 1) the ease of fabrication and operation, 
and 2) well-defined surface area. Unlike monolith fabrication or particle packing, the 
fabrication of micropillars is straightforward with no need for additional postprocessing, 
thereby speeding up the fabrication process. In the author’s experience, retaining magnetic 
particles inside microchannels using external magnets is extremely challenging and difficult 
to reproduce. Unlike with monoliths, the surface area of the pillar array is precisely defined, 
facilitating quantitation of enzyme coverage. Furthermore, pillar arrays are not as prone to
clogging as monoliths, further streamlining the microreactor operation. 
OSTE was chosen as the chip fabrication material because of its many advantageous 
features, discussed in section 2.3.2. Most notably, these include the tunable surface 
chemistry that allows the facile functionalization of the microreactor surface and the unique 
capability of material-induced oxygen-scavenging on-chip. OSTE show very good optical 
transparency down to the UV-A region (<325 nm).145 This is especially important when 
optical detection of analytes is performed on-chip. While in this study the metabolites were 
analyzed off-chip, this property was nevertheless essential to enable the UV-induced 
biotinylation step in the microreactor functionalization protocol. No photoinitiator was used 
in the polymerization, both to ensure that the polymer surfaces had sufficient amount of 
free, unreacted thiol groups for functionalization and to facilitate the bonding of the chip 
layers. 
Syringe pumps were chosen as the actuation method because of their operational 
simplicity in comparison to pressure controllers. Using in-house 3D-printed chip holders
and commercial capillary connectors, the interfacing of chips and syringes was relatively 
straightforward with no need for adhesives. The somewhat larger dead volumes compared 
with integrated actuation solutions did not present a problem since the sample volumes were 
comparatively large (tens of microliters vs. dead volumes of a few of microliters) and the
reaction constituents were inexpensive and readily available.
While it is possible to integrate detection elements with microfluidic chips, the selective 
detection of metabolites is usually possible only after a separation step, which further 
complicates the necessary chip design. Consequently, this study focused only on validating
of the biological relevance of the developed microreactor platform, and metabolite analysis 
was done off-chip. The range of studied substrates was very diverse; some substrates were 
compatible with straightforward fluorescence detection with a well-plate reader (a 
particularly useful quality for the method development phase), while others required more 
demanding methods, such as LC-MS/MS analysis. The use of off-chip metabolite detection 
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offered the needed flexibility for the analysis of a host of different analytes with varying 
properties. 
Given the proof-of-concept nature of this study, integration of different functional units 
on the chips was kept to a minimum. Additional elements, such as integrated heaters188,189
or gradient generators.190 would have inevitably complicated the fabrication process and 
decreased chip fabrication yields, while not offering any added value at this early stage of 
development. As a notable exception, the integration of an oxygen-scavenging compartment 
with the microreactor unit was studied as a means of performing metabolic assays under a 
controlled oxygen environment (see section 5.5.2). 
5.2 Enzyme-immobilization using fusogenic liposomes
5.2.1 Method development
Biotinylation of microsomes
The lipid membrane biotinylation protocol developed in this thesis was based on the 
spontaneous fusion of biotin-tagged liposomes with lipid bilayers. In vivo, membrane fusion 
is an important phenomenon in processes ranging from exocytosis to protein trafficking and 
fetal development, and is usually governed by specialized fusion proteins.191,192 However, 
specific liposome compositions enable spontaneous lipid bilayer fusion even in the absence 
of fusion proteins. These fusogenic liposomes (FL) have already been utilized in the 
functionalization of cell membranes with various chemistries181,182,193 and as drug 
nanocarriers for intracellular proteins.194 The rationale behind the selection of liposome 
composition is elaborated below.
The ability of lipid bilayers to form fusion intermediate states depends on the lipid 
composition. The fusion propensity of liposomes is determined by the curvature of the
monolayer formed spontaneously by the lipid: Lipids with a positive curvature (monolayers 
bulged in the direction of the polar heads) tend to inhibit the formation of fusion 
intermediates, whereas lipids with a negative curvature promote intermediates. Fusion can
also be promoted by sufficiently close contact of the two bilayers,191,192 which can be 
induced by incorporating positively charged lipids into the liposome composition.195,196 The 
close contact of the membranes results in a mutual surface-charge neutralization, and 
membrane contact is further enhanced by the loss of water molecules bound by hydrogen 
bonding to the membrane surface.195 Another factor affecting liposome fusogenicity is 
liposome size, with the smallest liposomes being the most fusogenic. Increased membrane 
tension in small liposomes is hypothesized to drive the evolution of intermediary structures 
into fusion pores.197,198
Based on these principles, the liposome lipid composition used in this study was tailored 
to favor spontaneous fusion with the HLM vesicles. DOPE is a neutral lipid that shows 
negative curvature and promotes fusion. DOTAP has a net positive charge, promoting close 
contact between the liposomes and the negatively charged HLM. The fluorescent DOPE 
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tagged with lissamine rhodamine B serves a dual function. While the fluorescence allows
the monitoring of b-HLM immobilization via fluorescence microscopy, the polarization of 
the delocalized π-electrons in the rhodamine moieties also induces membrane instabilities 
and disorders that promote fusion.181,191
Prior to fusion with HLMs, the multilamellar liposomes (average hydrodynamic radius 
493 ± 87 nm, n=4 batches), resulting from re-solvation of the dry lipid film into PBS were 
extruded to yield unilamellar liposomes with a reduced diameter (220 ± 25 nm, n=4
batches). Upon mixing, the opposite charges of the HLM (-44.3 ± 4.9 mV) and the fusogenic 
liposomes (69.3 ± 1.8 mV) facilitated fusion by promoting close contact. The occurrence of 
liposome fusion was verified spectroscopically based on a previously described protocol.199
Briefly, the rhodamine B fluorophore included in the liposome composition has a self-
quenching propensity that is proportional to its surface density. Liposome fusion with 
unlabeled membranes and the consequential decrease in surface density results in an 
increase in fluorescence intensity (Figure 13), which can be taken as an indication of 
successful fusion.
Figure 13. Fluorescence signal (ex 560/ em 583) of fusogenic liposomes (FL) with and without 
the presence of human liver microsomes (HLM) (liposome-HLM ratio 1:10).
Microreactor functionalization and enzyme immobilization
The robustness of the microreactor functionalization protocol, in terms of the effects of bulk 
monomer composition and biotin and streptavidin concentrations, was determined by 
measuring the amount of immobilized streptavidin and b-HLM based on their respective 
fluorescent tags (Figure 14A-C) (Publication I). Changes in surface properties after each 
functionalization step were also assessed by changes in water contact angles (Figure 14D). 
The amount of bound streptavidin increased with increasing amounts of biotin, which could 
be altered by either the number of free surface thiols or the concentration of the biotin-PEG 
used for initial surface functionalization. However, the amount of immobilized b-HLM was 
inversely proportional to the amount of bound streptavidin. Excess streptavidin on the 
reactor surface likely caused steric hindrance that hindered biotin-streptavidin binding. For 
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all further experiments, 0.1 mM biotin, 0.5 μg/mL streptavidin, and a 25% molar excess of 
thiol functional groups were used, as this was shown to result in highest amount of bound 
b-HLM compared with other tested conditions. 
 
Figure 14. The effect of A) thiol-ene molar ratio, B) biotin, and C) streptavidin concentration on 
the binding efficiency of streptavidin (StrA*) and biotinylated fusogenic liposomes (b-FL**) on 
thiol-ene micropillar surfaces as quantified by fluorescence microscopy (n= 3 IMERs in each 
case, streptavidin: ex 488/em 500–700 nm; b-FL ex 546/em 575–640 nm). D) A schematic of the 
functionalization protocol with inlays of fluorescence microscopy pictures and water contact angle 
measurements of thiol-ene surfaces (25% molar excess of thiol monomers) after each step of the 
functionalization protocol. Adapted with permission from ref. 183. © 2019 John Wiley and Sons. 
The specificity of the functionalization protocol was verified by sequentially omitting one 
step of the functionalization and determining the mean cumulative amount of metabolite 
produced in a 60 min time period from three parallel IMERs. Although some nonspecific 
binding of both streptavidin and b-HLM can be seen in the fluorescence characterization, 
the activity of IMERs prepared using the optimized protocol showed significantly higher 
activity compared to the samples where one or more functionalization steps were omitted 
(p < 0.0001, one-way ANOVA followed by Dunnett’s test, Figure 15A). This suggests that 
the proper binding of b-HLM is contingent on each step of the protocol and any 
nonspecifically bound enzymes will leak out of the reactor upon the application of flow. 
The CYP and UGT activities of immobilized b-HLM were also shown to be dependent on 
the reaction temperature, as expected based on the behavior of native non-immobilized 
HLM (Figure 15B). To demonstrate the universal applicability of the developed 
immobilization method, the protocol was also successfully applied to recombinant CYP2D6 
and CYP3A4 enzymes expressed in insect cells (Supersomes) (Figure 15C). The average 






rinse solution after immobilization using the colorimetric bicinchoninic acid assay,200 and 
subtracting this from the amount of protein in the filling solution. Based on the assay, the 
average amount of immobilized protein was 0.021 ± 0.010 mg (n=4 microreactors).   
 
Figure 15. Characterization of the IMER performance. A) Cumulative metabolite production 
(over 60 min) of CYP-IMERs prepared by sequentially omitting each of the steps in the 
functionalization protocol. The model reaction used was Luciferin-H hydroxylation via CYP2C9. 
Error bars denote the standard deviation between n=3 microreactors in each case. B) 
Temperature-dependence of CYP and UGT activities of immobilized b-HLM, as assayed using 
coumarin (CYP2A6) and 8-hydroxyquinoline (multi-UGT substrate) as probe substrates. Activity 
at 37 °C was set as 100%. Error bars denote the standard deviation between n = 3 IMERs in each 
case. *p-value < 0.05 (Student’s t-test). C) Relative activity of IMERs featuring immobilized HLM 
or different immobilized recombinant CYP enzymes (rCYP). The specific probe substrates used 
were Luciferin-H (HLM, CYP2C9), Luciferin-IPA (rCYP3A4), and Luciferin-ME EGE (rCYP2D6) 
(n=2 IMERs each). 
5.2.2 Protocol validation 
For an immobilization method to be truly applicable for the study of drug metabolism the 
applied processing should not alter enzyme kinetic parameters, otherwise the results cannot 
be reliably extrapolated to the in vivo context. In addition, the immobilization of the enzyme 
should not compromise enzyme activity or stability. The immobilization method developed 
in this thesis was validated for both the kinetics and stability of CYP- (Publication I) and 
UGT-catalyzed (Publication II) reactions. 
 
Enzyme kinetics 
The effect of immobilization on enzyme kinetics was evaluated by immobilizing b-HLM 
on streptavidin-coated magnetic particles as described in section 4.4.2. (Publication I). Only 
CYP enzymes were investigated in this preliminary characterization in order to focus 
specifically on the effects of biotinylation and subsequent immobilization on enzyme 
kinetics. CYPs reside on the cytosolic side of the microsomal membrane12 and are freely 
accessible to substrate binding in the absence of steric or diffusional constraints imposed by 
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of the membrane,17 are complicated by the mass transfer limitation caused by the intact 
microsomal membrane. This will be discussed in more detail in section 5.4.
In addition to CYP2A6, which was used for the initial method development, enzyme 
kinetic parameters were also determined for three CYP isoforms most often involved in the
metabolism of pharmaceuticals—CYP3A4, CYP2C9 and CYP2D67—using enzyme-
specific substrates. For each enzyme tested, the KM values of the immobilized b-HLM were 
comparable to values obtained using native, non-immobilized HLM (Table 8). This
confirmed that the developed immobilization strategy does not suffer from impaired 
diffusion, a typical issue in entrapment approaches that often leads to several-fold increases 
in apparent KM.92 Since the protein itself is not targeted in the biotinylation process, this
method also leaves the active sites of the CYPs better accessible compared to other
approaches, such as those based on covalent bonding.96,97
Table 8. KM values determined for different CYP enzymes (±standard error) in non-
immobilized HLM or immobilized on commercial streptavidin-coated magnetic beads. In each 
case, n=2 independent incubations in each case. 
Enzyme KM (μM)
Nonimmobilized Immobilized
CYP3A4 5.2 ± 0.5 15.8 ± 1.2
CYP2C9 75.1 ± 5.3 116.4 ± 37.3
CYP2D6 21.0 ± 2.4 32.0 ± 5.2
CYP2A6 2.9 ± 0.3 2.2 ± 0.5
Enzyme stability
Comparison of the enzyme activities of native HLM and b-HLM confirmed that the 
biotinylation process did not significantly alter the activity of soluble CYP (Publication I)
(Figure 16A). This was expected since the biotinylation process does not require any 
covalent modifications to the enzyme itself, which could result in enzyme inactivation. The 
stability of immobilized b-HLM was further studied by immobilizing b-HLM on 
streptavidin-functionalized magnetic particles. No significant loss of CYP activity was 
observed with immobilized b-HLMs even after two weeks of storage at 4 °C (Figure 16B).
By contrast, negative controls prepared by solubilizing non-biotinylated HLMs on lipid-
coated magnetic beads lost half of their activity after 6 days. Upon repeated incubations, the 
CYP activity started to decrease, typically halving after each incubation cycle. This was 
likely caused by incomplete recovery of the beads during the incubation and washing steps 
of the assay protocol. Similar loss of activity was also reported by Schejbal et al., when 
immobilizing recombinant microsomal CYPs on magnetic particles.96
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Figure 16. Effect of biotinylation and immobilization on HLM CYP activity. A) The relative 
activity of nonimmobilized HLM and nonimmobilized b-HLM as a function of time. The activity 
normalized with respect to that of native HLM at 30 min. Data from two independent samples is
shown. B) Relative activity (% of initial activity on day of immobilization i.e. day 0) of b-HLM and 
HLM (negative control) immobilized on streptavidin-functionalized magnetic beads on consecutive 
incubation cycles, after 6 or 15 days of storage at 4 °C. Error bars denote the standard deviation 
between n=4 batches of beads in each case. *p-value < 0.05. 
When b-HLM was immobilized inside the OSTE microreactors, CYP activity showed a 
considerable decline over time (halving over in 1-2 h) when assayed with specific probe 
reactions for both CYP2C9 and CYP2C8. Further investigations indicated that this issue 
was linked to thiol monomers leaching out of the bulk polymer. These material properties 
of thiol-enes will be discussed in more detail in Chapter 5.3.
Similar to CYPs, the biotinylation process was shown not to compromise UGT activity
(Publication II). In fact, there was a small (ca. 25 %) but statistically significant (p=0.02, 
Student’s t-test) increase in glucuronidation activity with biotinylated HLM compared to 
native HLM (Figure 17A). This can possibly be explained by the relative increase of long-
chain fatty acids in biotinylated HLM, which has been reported to elevate UGT activity.201
Non-lamellar lipids, such as DOPE, have also been reported to promote the membrane 
permeation of small molecules.202 The observed increase in glucuronidation activity was, 
however, negligible compared to that achieved by pre-incubation with alamethicin, 
suggesting that biotinylation does not result in physical membrane disruption resembling
alamethicin-induced pore formation. The UGT activity of b-HLM immobilized inside
OSTE microreactors proved to be highly stable, featuring a negligible decrease in enzyme 
activity within the first 10 h of continuous use, and a rather minor decrease during the 
subsequent 5 h period (Figure 17B). This further proves that the immobilization method 
developed herein is robust and that the inactivation of immobilized CYPs is not a result of 
immobilized HLM leaching out of the IMER.
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Figure 17. Effect of biotinylation and immobilization on UGT-activity of HLM. The effect of 
alamethicin (ala) on the glucuronidation rate in native HLM and biotinylated HLM (b-HLM) in 
static conditions. Error bars present the variation between n=3 reactors. **p-value < 0.005 
(Student’s t-test), n.s.=non-significant. B) The stability of the UGT activities of two parallel 
microreactors over a 15-hour-long experiment at a flow rate of 2.5 μL/min. Activities were
normalized with respect to the maximum activity of each reactor. 50 μM 8-hydroxyquinoline was 
used as the probe substrate in all experiments. Adapted from ref. 203. © 2020, Kiiski et al.; 
Elsevier, CC-BY-NC-ND 4.0.
5.3 Material interactions
The leaching of uncrosslinked thiol and allyl monomers from the bulk OSTE polymer has 
been observed in previous studies156,204 and was also verified in this thesis by titration (see 
section 5.5.1). The magnitude of monomer leaching is dependent on the polymer 
composition used. This study examined the effect of the leaching thiols on CYP- and UGT-
mediated reactions in more detail.
5.3.1 CYP metabolism
When CYP metabolism was studied with b-HLM immobilized inside thiol-ene 
microreactors, considerable decline in the CYP activity was observed with both CYP2C9 
and CYP2C8 (Figure 18A). The decline of enzyme activity as a result of issues related to
the immobilization procedure (e.g., poorly attached enzymes leaching out of the reactor),
could be reliably ruled out based on the UGT activity data (Figure 17B). To study whether 
instead the leaching thiol monomers could affect CYP metabolism, IC50 values were 
determined for both of the used thiol monomers (tetra- and trithiol) toward CYP2C9 in this 
study. Both monomers showed similar inhibitory potential that was potentiated by a 30-min 
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Figure 18. A) CYP2C9 and CYP2C8 activity of b-HLM immobilized in thiol-ene microreactors 
as a function of time. Activities were normalized with respect to the maximum activity of each 
reactor. Luciferin-H (CYP2C9) and paclitaxel (CYP2C8) were used as probe substrates at 
concentrations of 200 and 5 μM, respectively. Error bars denote the standard deviation between 
n=4 microreactors in each case. Inhibitory effect of B) tetrathiol and C) trithiol monomers on the 
metabolic activity of CYP2C9, as assayed using luciferin-H as a probe substrate with or without a 
30 min preincubation with NADPH. Activities are expressed as percentages of the inhibitor-free 
solvent control. All samples were performed in duplicates.
5.3.2 UGT metabolism
While the leaching thiol monomers were found to inhibit CYP activity in a time-dependent 
manner even at rather low concentrations, the activity of UGT enzymes immobilized inside 
thiol-ene microreactors was unaffected by both the tetrathiol and triallyl monomers. This is
evidenced by both the long-term stability of UGT activity (Figure 17B) and IC50 assays 
performed with both monomers used in the microreactor fabrication (Figure 19).

























































Figure 19. The impact on UGT activity (8-hydroxyquinoline glucuronidation) in human liver 
microsomes of A) tetrathiol and B) triallyl monomers dissolved in the incubation matrix. 
Incubations were performed in duplicate. Adapted from ref. 203. © 2020, Kiiski et al.; Elsevier, 
CC-BY-NC-ND 4.0
On the basis of these results, it can be concluded that the detrimental, material-induced 
effects of leaching monomers is a factor that should be carefully assessed in each specific 
application. The monomer ratio of thiol and allyl monomers has been shown to affect the 
amount of leaching monomers.156 This should be studied further in order to minimize 
detrimental effects on enzymes, particularly for long-term assays with CYPs. However, 
alterations to the monomer ratio will also have effects on the surface chemistry of the 
reactor, impacting the efficiency of surface functionalization. For example, IMERs 
fabricated from stoichiometric compositions of tetrathiol and triallyl showed only trace 
amounts of CYP-activity (data not shown), presumably due to the low density of free thiols 
on the surface.
5.4 Enzyme kinetic determination in flow-through conditions
In the case of UGT enzymes, the determination of enzyme kinetics is complicated by 
two factors that can result in drastic underestimation of in vivo clearances.43 First, the active 
site of UGT enzymes resides on the luminal side of the microsomal membranes, meaning 
that substrates, cosubstrates and metabolites have to cross the membrane. This imposes a 
mass transfer limitation that has to be eliminated by disrupting the membrane in order to
reach maximal enzyme activity.44,45 Second, free fatty acids leaching from the microsomal 
matrix have been shown to inhibit some UGT isoforms.46–48 The mechanisms behind both
of these phenomena were studied utilizing flow-through conditions enabled by enzyme 
immobilization (Publication II).
Under flow conditions, the diffusion of the reaction components across the immobilized 
microsomal membrane eventually reaches a steady-state (Figure 20A), which is observed 
as the plateauing of UGT activity to a constant value, regardless of whether the membrane 
is intact. At high flow rates (15 μL/min), preincubating the microreactor with alamethicin 
resulted in a 2-fold increase in UGT-activity due to the elimination of diffusional 


































restrictions. By adding alamethicin to the feed solution, an even greater increase in the UGT 
activity (ca. 3-fold) was achieved as soon as the steady-state was reached (Figure 20A). 
However, besides alamethicin, flow rate has a great impact on steady-state formation as it
controls the residence time of the substrate within the system. When the residence time of 
the substrate increases with lower flow rates, the impact of alamethicin becomes negligible. 
When the amount of metabolite produced per collected fraction was further compared at 
different flow rates, it was evident that the reaction was not diffusion limited as the amount 
of metabolite increased linearly with increasing residence times both in the presence and 
absence of alamethicin (Figure 20B). The reaction velocities (pmol/min/mg protein) 
determined for the microreactor reactions at steady-state correlated well with the activities 
in the static assays with alamethicin (see Publication II for details), and were substantially 
higher than activities in static assays in the absence of alamethicin. In summary, in flow-
through conditions, the steady-state velocity can be distinguished from the initial (diffusion-
limited) velocity, obviating the need for membrane disruption. 
Figure 20. The effect of alamethicin on UGT activity of immobilized HLM in flow-through 
conditions. A) The impact of alamethicin on the time for steady-state formation in a microreactor 
operated at a flow rate of 15 μL/min. Error bars denote the standard deviation between n=4 
microreactors in each case. B) The impact of residence time on the amount of 8-hydroxyquinoline-
glucuronide formed in the reactor in the absence of alamethicin and with alamethicin included in 
the feed solution. Error bars denote the standard deviation between n=4 microreactors in each 
case. Adapted from ref. 203. © 2020, Kiiski et al.; Elsevier, CC-BY-NC-ND 4.0
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The kinetics of immobilized UGTs under flow conditions were further investigated by 
determining the enzyme kinetic parameters of the antiviral drug zidovudine. Zidovudine is 
a specific UGT2B7 substrate, whose metabolism is significantly inhibited by free fatty acids 
and thus typically underestimated in in vitro studies43 unless albumin—capable of binding
the inhibitory fatty acids—is added to the in vitro enzyme incubations.46 The effect of 
albumin on zidovudine glucuronidation kinetics were studied with both non-immobilized, 
native HLM and immobilized b-HLM. As alamethicin did not have an effect on the steady-
state activity of UGT reactions, it was excluded from the enzyme kinetic experiments.
With non-immobilized, native HLM in static conditions, the presence of albumin halved 
the KM of the enzyme, as expected, but had no effect on Vmax unless the microsomes were 
pretreated with alamethicin. In the absence of alamethicin, in vitro intrinsic clearance 
(CLint) increased by 3-fold (from 24 ± 2 nL/min/mg to 73 ± 6 nL/min/mg microsomal 
protein), while the presence of alamethicin resulted in a 10-fold increase in the CLint (to 
268 ± 17 nL/min/mg microsomal protein).
In flow-through conditions, the determination of enzyme kinetics was facilitated by the 
creation of substrate concentration gradients using two interconnected syringe pumps. At 
each substrate concentration, three subsequent fractions were collected at a flow rate of 
5 μL/min, corresponding to a reaction time of 3.7 min. The last fraction was quantified to 
ensure that the steady state velocity had been reached and to calculate the kinetic constants. 
In the absence of albumin, on-chip zidovudine glucuronidation followed Michaelis-Menten 
kinetics with a slightly higher KM (2572 ± 718 μM) compared to that obtained for native 
HLM in similar conditions (1511 ± 146 μM) (Table 9). The presence of albumin reduced
the KM value of on-chip zidovudine glucuronidation by about half (790 ± 190 μM), close to 
the value determined for native HLM in the presence of albumin. On the other hand, the 
Vmax values derived from microreactor experiments were somewhat larger when compared 
to those determined in static assays with or without added alamethicin. This resulted in 
comparable CLint values between the microreactors without alamethicin and static assays 
with alamethicin. These results suggest that conducting drug glucuronidation assays under 
flow-through conditions could likely improve correlation of microsomal in vitro results with 
in vivo drug clearance over static assays, without the need for membrane-disrupting agents 
such as alamethicin.
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Table 9. Comparison of zidovudine glucuronidation kinetics in static (HLM) and flow-
through conditions (b-HLM) (±standard error). For soluble HLM, the samples were assayed 
in duplicate with and without bovine serum albumin (0.1 % w/v) and/or alamethicin (50 
μg/mL). For the microreactors, kinetics were determined with and without albumin by 
quantifying the metabolite from the third fraction (à 50 μL) collected after the feed 
composition had been changed (n=3 microreactors). 
Enzyme
source





No No 1511 ± 146 36 ± 1 24 ± 2
No Yes 3430 ± 238 163 ± 5 48 ± 4
Yes No 505 ± 40 37 ± 1 73 ± 6
Yes Yes 549 ± 33 147 ± 3 268 ± 17
b-HLM
No No 2572 ± 718 274 ± 35 107 ± 33 
Yes No 791 ± 190 306 ± 23 387 ± 97
The presence of flow in the microreactor assays was initially thought to remove any 
inhibitory fatty acid artifacts, thus obviating the need for albumin addition. However, even 
in flow conditions albumin had a clear lowering effect on KM. This may indicate that
inhibitory fatty acid artifacts are accumulated on the luminal side of the membrane as well, 
and albumin helps sequester the fatty acids upon their partitioning across the microsomal 
membrane. Interestingly, Horspool et al.206 recently reported a method for binding HLM on 
silica-coated magnetic beads, which was shown to lower the KM of zidovudine
glucuronidation. This was hypothesized to be caused by the elimination of free fatty acids 
during the multiple washing steps in the protocol. Further study is warranted to investigate
the possibility that the fatty-acid-eliminating effect of the immobilization procedure could 
be more prominent if the enzyme kinetics are determined using streptavidin-coated particles 
similar to CYPs.
5.5 Drug metabolism assays under controlled oxygen 
environment
5.5.1 Oxygen scavenging of thiol-enes
The oxygen scavenging capability of OSTEs has been previously characterized using 
OSTE+ formulations, which include a heat-curable epoxy component in addition to thiol 
and allyl (ene) monomers.180 The oxygen scavenging capability of OSTE+ was associated 
with the oxidation of thioether-linkages in the polymer bulk. Heat treatment of the polymer 
was shown to significantly decrease the oxygen scavenging rate, which was associated with 
increased Tg and thus decreased oxygen permeability to the bulk.180
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In this study, the impact of bulk polymer composition on the oxygen depletion rate of 
pure thiol-enes was studied in more detail by varying the monomer ratio in the bulk from a
50 % molar excess of thiols to a stoichiometric ratio of thiols (tri- or tetrathiol) and allyls 
(triallyl). The impact of heat treatment (110 °C) and degree of cross-linking was also 
studied.
In microchannels fabricated using both tetrathiol (Figure 21A) and trithiol (Figure 21B) 
monomers, the oxygen depletion rate followed first order kinetics and was dependent on the 
relative amount of thiol and allyl components in the bulk polymer. The reaction constant (k)
was shown to be greater for tetrathiol-containing polymers than trithiol-containing polymers 
and increased along with increasing excess of the thiol component in the bulk (see 
Publication III for details). Heat-treating the microchannels after curing (110 °C overnight) 
markedly slowed the oxygen depletion rate for both thiol monomers. Contrary to previous 
reports,180 the effect of heat-treatment could not be explained by changes in the polymer Tg,
which reflects the oxygen permeability of the bulk polymer.207 Tg was practically unaffected 
by heat treatment in the case of both trithiol-containing (2.2→3.1 °C, n=1 measurement)
and tetrathiol-containing (25.9→26.6 °C, n=1 measurement) compositions. Furthermore, 
the oxygen permeability determined for polymers fabricated using trithiol (3.0 ± 0.6 cc 
cm/m2 day atm) was approximately 3-fold higher than that of the polymer fabricated from
tetrathiol (1.0 ± 0.007 cc cm/m2 day atm) using the same molar excess of thiol groups (50%) 
in the bulk. If oxygen permeability from solution to the bulk was the rate determining step 
in oxygen depletion, the use of trithiols should have accelerated the speed of the depletion, 
contrary to observations. However, differences in permeability might explain the plateauing 







Figure 21. Oxygen depletion as a function of time in thiol-ene microchannels (30×2×0.2 mm) 
fabricated with different monomer ratios using A) tetrathiol or B) trithiol as the thiol-containing 
monomer. n=4–8 microreactors in each sample group. HT = heat treatment (110 °C overnight) C) 
Oxygen depletion in either thiol-rich (+25 mol-%) or allyl-rich (+25 mol-%) bulk compositions 
made using tetrathiol. PI refers to added photoinitiator (Irgacure® TPO-L, 0.1 % m/v) in the bulk 
composition. D & E: Oxygen scavenging by dissolved D) tetrathiol and E) trithiol monomers (in 
water) as a function of time. 
The mechanism of oxygen depletion in thiol-ene channels was traced back to the oxidation 
of uncrosslinked thiol monomers leaching from the bulk polymer. In this case, the oxygen 
depletion rate should correlate with the amount of free (uncrosslinked) monomers in the 
bulk. This hypothesis was tested by manipulating the amount of the uncrosslinked tetrathiol 
monomer with the help of a photoinitiator and by using opposite excess (+25 mol-%) of 
thiol and allyl functional groups in the bulk. The addition of the photoinitiator to the thiol-
rich composition did not visibly affect the oxygen depletion rate constant compared with 
photoinitiator-free, thiol-rich composition (Figure 21C), even if the Tg was substantially 
increased with the addition of the photoinitiator (13→42 °C). However, using allyl-excess 
decreases the amount of free thiol monomer in the bulk, and was shown to decrease the rate 
constant substantially. These observations confirmed that the oxygen scavenging rate in 
thiol-ene channels was mostly governed by the chemical composition of the bulk, 
particularly the amount of uncrosslinked thiol monomers, and was rather independent on 
the mechanical bulk properties, such as Tg.  
When the free trithiol and tetrathiol monomers were dissolved in an aqueous media, both 
monomers demonstrated an ability to scavenge oxygen from the solution (Figure 21D-E). 
This experiment was performed at high micromolar concentrations (100 and 1000 μM) and 
revealed that the oxygen depletion rate does not markedly depend on the thiol monomer 
concentration, until the thiol component is completely consumed (e.g., at approximately 
A) B) C)
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120 min for tetrathiol, Figure 21D). The omission of a photoinitiator from the polymer 
fabrication is known to result in incomplete conversion of polymers, even when a 
stoichiometric ratio of functional groups is used.153,208 The extent of monomer conversion 
is also known to decrease as a function of layer depth.209 In replica molding, this results in 
a low degree of cross-linking at the channel surface, the point furthest from the UV light 
source during the curing step. These factors likely explain the effective elimination of 
oxygen in microchannels made of even stoichiometric thiol-ene compositions. The impact 
of heat treatment was associated with the evaporation of uncrosslinked thiol monomers from 
the bulk polymer, rather than changes in the oxygen permeability of the bulk polymer, as 
reported previously by Sticker et al.180
To further confirm that leaching monomers, not surface thiols, were responsible for the 
oxygen depletion, the amount of thiol monomers leaching out of a micropillar microchannel 
(25% excess of tetrathiol) was determined. The amount of leaching tetrathiols over time was 
quantified after surface passivation. This experiment confirmed that the mass transfer of 
tetrathiol from the bulk follows first-order kinetics (Figure 22A), similar to oxygen 
depletion in thiol-ene microchannel in static conditions. Thus, it was hypothesized that the 
diffusion of thiols across the polymer-liquid interface is the rate limiting step for oxygen 
depletion in OSTE microchannels, and that the diffusion rate is most dependent on the 
amount of uncrosslinked thiols in the bulk.
Figure 22. A) The leaching of tetrathiol monomers inside a thiol-ene micropillar channel 
quantified using DTNB (5,5’-dithiobis[2-nitrobenzoic acid], “Ellman’s reagent”). The free 
surface thiols were first neutralized by an incubation with 1 mM DTNB for 30 min, followed by 
consecutive incubations of 10, 20 and 30 min. Error bars denote standard deviation from n = 6 
individual micropillar channels. B) The effect of channel surface-to-volume ratio (A/V) on oxygen 
scavenging kinetics in channels fabricated using thiol-rich (+25 mol-%) tetrathiol-containing 
polymer. n=3 individual channels.
Assuming that the diffusion of thiol monomers across the polymer-liquid interface is the
rate limiting step for oxygen depletion, the oxygen depletion rate should be dependent on 
the surface-to-volume ratio of the microreactor. The effect of surface-to-volume ratio was 
studied by comparing the O2 consumption rate in a rectangular channel (2×30×0.2 mm,
surface-to-volume ratio of 6 mm-1) vs. in a micropillar array channel (Design 1, surface-to-
B)A)
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volume ratio of 30 mm-1), in static conditions. In both cases, oxygen depletion displayed 
first order kinetics, with the rate coefficient k being directly proportional to the surface-to-
volume ratio (Figure 22B).
5.5.2 On-chip metabolism assays under controlled oxygen environment
In recent years, numerous approaches for oxygen control in microfluidic systems have been 
introduced.210,211 These platforms often rely on multi-compartment designs comprised of a 
separate cell culture compartments and oxygen control compartments, separated by a gas-
permeable membrane. The gas content in the oxygen control compartment is usually 
regulated by an external gas supply212,213 or supplemented reducing agents.214,215 While 
these approaches permit the precise control of the oxygen microenvironment, they do so at 
the cost of complex, multicompartmental designs.
The omission of a photoinitiator also facilitates the unique oxygen scavenging property 
of OSTE, which was linked to leaching thiol monomers due to a lower degree of cross-
linking. This property was crucial for the implementation of the on-demand tuning of 
oxygen partial pressure on-chip studied in Publication III. However, the thiol monomers 
were also shown to have an inhibitory effect on CYPs, which should be taken into account 
when carrying out metabolic assays on thiol-ene-based systems. The inherent ability of 
OSTE materials to scavenge dissolved oxygen from aqueous solutions shows great potential 
for simple implementation of oxygen control in microfluidic settings. Based on the initial 
material characterization of thiol-enes (see section 5.5.1), a chip design capable of tuning 
the oxygen partial pressure inside a microfluidic channel was designed. In this design, the 
oxygen control was based solely on the geometry of the chip and the tuning of flow rate
ratios, obviating the need for supplementary reducing agents or complicated, multi-
compartmental chip designs (Design 2, Figure 9, Figure 23A-B).
The design featured six serially connected micropillar channels (responsible for the 
scavenging of oxygen) junctioning with a second inlet supplying air-saturated fluid. From 
the junction the flow continues to a seventh micropillar unit comprising immobilized HLM. 
Based on oxygen scavenging kinetics, the length of the oxygen scavenging unit (defining 
the reaction time) was scaled to allow near anoxic conditions at the end of the oxygen 
scavenging channel with flow rates (residence time) up to 5 μL/min (Figure 23C). At this 
flow rate regime, the drop in oxygen partial pressure inside the final microreactor 
compartment was confirmed to be negligible (Figure 23D), which ensured that the oxygen 
content inside the IMER compartment could be reliably tuned by adjusting the flow rate 







Figure 23. A) Schematic of the chip design comprising an oxygen scavenging unit (blue), with an 
inlet Q1 and an outlet Q2, monolithically integrated with an immobilized enzyme microreactor 
(IMER) unit (red) with Y-junction providing air-saturated feed solution from inlet Q3 and an 
outlet Q4 for collecting metabolite samples. Oxygen level inside the microreactor was controlled 
by tuning the flow rate ratio of flows Q2 (oxygen-depleted) and Q3 (air-saturated). B) Photograph 
of the oxygen level measurement setup. C) Oxygen level (% of air-saturated O2) at the end of the 
oxygen scavenging section as function of different residence times. n=3 chips. D) Oxygen level (% 
of air-saturated O2) at the end of a single micropillar array channel as a function of different 
residence times. n=3 chips. Corresponding flow rates are denoted on the upper x-axis. 
The applicability of the platform for performing drug assays under controlled oxygen 
environment was demonstrated by studying the reductive metabolism of zidovudine. In 
addition to glucuronidation, zidovudine can also be metabolized to 3’-amino-3’-
deoxythymidine (AMT) by the reduction of the drug’s azide group into an amine.69 AMT is 
a myelotoxic metabolite, hypothesized to play a role in the bone marrow suppression that 
occurs as a side effect of zidovudine therapy.216 The specific mechanism of this NADPH-
dependent reaction is unresolved, but it is understood to involve POR, cytochrome b5, and 
CYPs.217 The pathway is known to be oxygen-sensitive, with the presence of oxygen 
inhibiting the production of AMT either partially218 or completely.219  
First, the ability of the design to control the oxygen partial pressure inside the channel 
on-demand with the adjustment of flow rate ratios was verified. As expected, the actual 
measured oxygen levels inside the microreactor (Figure 24A) were in good agreement with 
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Figure 24. A) Photograph of the chip design comprising an oxygen scavenging unit (filled with 
red dye integrated with n microreactor unit (filled with green dye). B) Tuning of oxygen levels 
inside a microfluidic chip by mixing oxygen-rich (Q3) and oxygen-depleted (Q2) flows (shown as a 
function of flow rate ratio). n=3 chips. C) Schematic of the oxygen-sensitive metabolism of 
zidovudine. D) Demonstration of the oxygen-sensitive reductive metabolism of zidovudine on-chip. 
n=4 chips. Abbreviations: AZT: zidovudine; AMT, 3’-amino-3’-deoxythymidine; AZT-G, 
zidovudine glucuronide.  
Finally, the oxygen-sensitivity of the reduction of zidovudine to AMT was demonstrated 
on-chip (Figure 24C-D). The rate of zidovudine reduction increased approximately 10-fold 
when oxygen was eliminated from the microreactor compartment. When the oxygen 
saturated flow was switched back on, the rate of zidovudine reduction dropped back to its 
initial level. On the other hand, the rate of oxygen independent zidovudine glucuronidation, 
which was also simultaneously monitored, was not markedly affected by the changes in 
oxygen partial pressure. This simple demonstration showcases the potential of the 





























































Preclinical drug metabolism research would benefit from assays implemented on 
microfluidic immobilized enzyme microreactors (IMER), but well-characterized IMERs 
comprising drug-metabolizing enzymes have been scarcely reported in the literature. This 
is presumably due to the methodological complexity of immobilizing membrane-bound
enzymes. The methodology developed in this thesis addressed this unmet need.
In Publication I, a novel approach for immobilizing membrane-bound enzymes was 
developed based on 1) the biotinylation of lipid membranes via spontaneous fusion with 
biotin-tagged liposomes with biological membranes and 2) the facile surface 
functionalization of off-stoichiometric thiol-enes (OSTE). Unlike in previously reported 
methods, both CYP and UGT enzymes immobilized using this method retained their activity 
and native enzyme kinetic parameters. This novel method therefore circumvents issues 
associated with conventional immobilization approaches, such as diffusion-limited kinetics 
and enzyme inactivation.
In Publication II, the microreactor platform was further characterized with respect to 
UGT-mediated phase II metabolism. The ability to perform UGT reactions under flow 
facilitated the determination of enzyme kinetics and the in-depth study of mechanisms 
behind the latency associated with UGT reactions in vitro.
In Publication III, the material-induced oxygen scavenging of OSTE was utilized to
enable the performance of metabolic assays under a controlled oxygen environment. The 
mechanism behind the oxygen scavenging phenomenon of OSTE was studied in detail and 
linked with thiol monomers leaching out of the polymer bulk. Based on this initial 
characterization, a chip design was devised that enabled the facile control of oxygen partial 
pressure inside the microreactor compartment based on the control of flow rate ratio of 
oxygen-depleted and oxygen-saturated flows. The ability to control the oxygen environment 
of on-chip metabolic reactions is a novel feature that has not been reported in any other 
drug-metabolizing enzyme microreactor platforms to-date.
The effect of the leaching thiol monomers responsible for oxygen scavenging on the 
enzyme activity of both CYPs and UGTs was also studied. UGTs were shown to be 
unaffected by the monomers, but CYPs exhibited time-dependent inhibition at mid-
micromolar concentrations of both tri- and tetrathiol monomers. This suggests that thiol 
monomers are irreversible inhibitors of CYPs. The consequent decline in CYP activity in 
IMERs is an issue that should be addressed in the future in order to enable long-term CYP 
assays.
The methodology developed in this thesis has already has already found use in several 
subsequent studies by other researchers, highlighting the practical feasibility of the concepts
developed here. For example, droplet-based enzyme microreactors have been successfully 
implemented on digital microfluidic platforms using the enzyme immobilization protocol 
developed in this thesis and porous thiol-ene monoliths as solid supports.188,220 The
immobilization method developed in this thesis has also been implemented on magnetic 
particles to study inter-individual differences in drug metabolism using digital 
microfluidics.221 Furthermore, the same microreactor platform has been used in the in-depth 
study of time-dependent inhibition of the CYP system under flow conditions.222 In addition 
74
to drug metabolism research, the characterization of the material-induced hypoxia of OSTE-
based systems carried out in this thesis are likely to find widespread use in many organ-on-
a-chip applications, including the ongoing work by the hosting research group.
Moving forward, the technology developed herein could additionally offer significant 
advantages over conventional in vitro assays in the pharmaceutical industry as well. These 
include increased throughput, intricate study designs in flow-through conditions and 
streamlined analysis enabled by the integration potential of microfluidic systems, to name 
a few. However, most microfluidic systems reported to-date have encountered difficulty 
when it comes to commercial utilization, falling into a sort of limbo between academia and 
industry often referred to as the “technological valley of death.” The work carried out in this 
thesis contributed to the validation of this novel IMER system in a laboratory setting, and 
the platform can be used in academic research to good effect. However, in order for the 
platform to become a viable commercial product, further optimization and standardization 
of the fabrication protocol are needed. That said, mass production of this microreactor 
platform could be possible with roll-to-plate fabrication technology.223
All in all, the microreactor platform developed in this thesis successfully addressed
many of the key shortcomings of current state of the art (i.e., static) in vitro assay 
methodologies and previously reported IMER platforms, and shows great promise as a
versatile toolbox for in vitro drug metabolism research. The thorough method development 
and validation of the IMER platform in this thesis paves the way for applications such as 
the mechanistic study of complex drug-drug interactions. Future work should also focus on




1. Wouters, O. J., McKee, M. & Luyten, J. Estimated research and development 
investment needed to bring a new medicine to market, 2009-2018. JAMA 323, 844–
853 (2020).
2. Smietana, K., Siatkowski, M. & Møller, M. Trends in clinical success rates. Nat. Rev. 
Drug Discov. 15, 379–380 (2016).
3. Hay, M., Thomas, D. W., Craighead, J. L., Economides, C. & Rosenthal, J. Clinical 
development success rates for investigational drugs. Nat. Biotechnol. 32, 40–51
(2014).
4. Guengerich, F. P. Common and uncommon cytochrome P450 reactions related to 
metabolism and chemical toxicity. Chem. Res. Toxicol. 14, 611–650 (2001).
5. Zanger, U. M. Introduction to drug metabolism. In Metabolism of drugs and other 
xenobiotics 285–300, John Wiley & Sons, Ltd (2012).
6. Döring, B. & Petzinger, E. Phase 0 and phase III transport in various organs: Combined 
concept of phases in xenobiotic transport and metabolism. Drug Metab. Rev. 46, 261–
282 (2014).
7. Williams, J. A., Hyland, R., Jones, B. C., Smith, D. A., Hurst, S., Goosen, T. C., 
Peterkin, V., Koup, J. R. & Ball, S. E. Drug-drug interactions for UDP-
glucuronosyltransferase substrates: a pharmacokinetic explanation for typically 
observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos. 32, 1201–1208
(2004).
8. Wienkers, L. C. & Heath, T. G. Predicting in vivo drug interactions from in vitro drug 
discovery data. Nat. Rev. Drug Discov. 4, 825–833 (2005).
9. Smith, H. S. Opioid metabolism. Mayo Clin. Proc. 84, 613–624 (2009).
10. Klimas, R. & Mikus, G. Morphine-6-glucuronide is responsible for the analgesic effect 
after morphine administration: a quantitative review of morphine, morphine-6-
glucuronide, and morphine-3-glucuronide. Br. J. Anaesth. 113, 935–944 (2014).
11. Zanger, U. M. & Schwab, M. Cytochrome P450 enzymes in drug metabolism: 
Regulation of gene expression, enzyme activities, and impact of genetic variation. 
Pharmacol. Ther. 138, 103–141 (2013).
12. Guengerich, F. P. Cytochromes P450. In Metabolism of Drugs and Other Xenobiotics
27–66, John Wiley & Sons, Ltd (2012).
13. Munro, A. W., Girvan, H. M., Mason, A. E., Dunford, A. J. & McLean, K. J. What 
makes a P450 tick? Trends Biochem. Sci. 38, 140–150 (2013).
14. Waskell, L. & Kim, J.-J. P. Electron transfer partners of cytochrome P450. in 
Cytochrome P450: Structure, Mechanism, and Biochemistry (ed. Ortiz de Montellano, 
P. R.) 33–68, Springer International Publishing (2015). 
15. Im, S.-C. & Waskell, L. The interaction of microsomal cytochrome P450 2B4 with its 
redox partners, cytochrome P450 reductase and cytochrome b5. Arch. Biochem. 
Biophys. 507, 144–153 (2011).
76
16. Šrejber, M., Navrátilová, V., Paloncýová, M., Bazgier, V., Berka, K., Anzenbacher, P. 
& Otyepka, M. Membrane-attached mammalian cytochromes P450: An overview of 
the membrane’s effects on structure, drug binding, and interactions with redox 
partners. J. Inorg. Biochem. 183, 117–136 (2018).
17. Tukey, R. H. & Strassburg, C. P. Human UDP-Glucuronosyltransferases: Metabolism, 
Expression, and Disease. Annu. Rev. Pharmacol. Toxicol. 40, 581–616 (2000).
18. Pelkonen, O., Turpeinen, M., Uusitalo, J., Rautio, A. & Raunio, H. Prediction of drug 
metabolism and interactions on the basis of in vitro investigations. Basic Clin. 
Pharmacol. Toxicol. 96, 167–175 (2005).
19. Issa, N. T., Wathieu, H., Ojo, A., Byers, S. W. & Dakshanamurthy, S. Drug 
metabolism in preclinical drug development: a survey of the discovery process, 
toxicology, and computational tools. Curr. Drug Metab. 18, 556–565 (2017).
20. Seibert, E. & Tracy, T. S. Fundamentals of enzyme kinetics. in Enzyme Kinetics in 
Drug Metabolism: Fundamentals and Applications (eds. Nagar, S., Argikar, U. A. & 
Tweedie, D. J.) 9–22, Humana Press (2014).
21. Ito, K., Iwatsubo, T., Kanamitsu, S., Nakajima, Y. & Sugiyama, Y. Quantitative 
prediction of in vivo drug clearance and drug interactions from in vitro data on 
metabolism, together with binding and transport. Annu. Rev. Pharmacol. Toxicol. 38,
461–499 (1998).
22. Houston, J. B. & Carlile, D. J. Prediction of hepatic clearance from microsomes, 
hepatocytes, and liver slices. Drug Metab. Rev. 29, 891–922 (1997).
23. Pelkonen, O. & Turpeinen, M. In vitro-in vivo extrapolation of hepatic clearance: 
biological tools, scaling factors, model assumptions and correct concentrations. 
Xenobiotica 37, 1066–1089 (2007).
24. Sproule, B. A., Naranjo, C. A., Brenmer, K. E. & Hassan, P. C. Selective serotonin 
reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin. 
Pharmacokinet. 33, 454–471 (1997).
25. Patsalos, P. N. & Perucca, E. Clinically important drug interactions in epilepsy: general 
features and interactions between antiepileptic drugs. Lancet Neurol. 2, 347–356 
(2003).
26. Guengerich, F. P. Role of cytochrome P450 enzymes in drug-drug interactions. in 
Advances in Pharmacology (ed. Li, A. P.) vol. 43 7–35, Academic Press (1997).
27. Friedman, M. A., Woodcock, J., Lumpkin, M. M., Shuren, J. E., Hass, A. E. & 
Thompson, L. J. The safety of newly approved medicines: do recent market removals 
mean there is a problem? JAMA 281, 1728–1734 (1999).
28. Lasser, K. E., Allen, P. D., Woolhandler, S. J., Himmelstein, D. U., Wolfe, S. M. & 
Bor, D. H. Timing of new black box warnings and withdrawals for prescription 
medications. JAMA 287, 2215–2220 (2002).
29. Ito, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H. & Sugiyama, Y. Prediction 
of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction 
in the liver. Pharmacol. Rev. 50, 387–412 (1998).
77
30. Tien, E. S. & Negishi, M. Nuclear receptors CAR and PXR in the regulation of hepatic 
metabolism. Xenobiotica 36, 1152–1163 (2006).
31. Fowler, S. & Zhang, H. In vitro evaluation of reversible and irreversible cytochrome 
p450 inhibition: current status on methodologies and their utility for predicting drug–
drug interactions. AAPS J. 10, 410–424 (2008).
32. Fasinu, P., Bouic, P. J. & Rosenkranz, B. Liver-based in vitro technologies for drug 
biotransformation studies - a review. Curr. Drug Metab. 13, 215–224 (2012).
33. Yung-Chi, C. & Prusoff, W. H. Relationship between the inhibition constant (KI) and 
the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic 
reaction. Biochem. Pharmacol. 22, 3099–3108 (1973).
34. Ghanbari, F., Rowland-Yeo, K., Bloomer, J., Clarke, S., Lennard, M., Tucker, G. & 
Rostami-Hodjegan, A. A critical evaluation of the experimental design of studies of 
mechanism based enzyme inhibition, with implications for in vitro-in vivo
extrapolation. Curr. Drug Metab. 7, 315–334 (2006).
35. Silverman, R. B. Mechanism-based enzyme inactivators. in Methods in Enzymology
vol. 249 240–283, Academic Press (1995).
36. Pelkonen, O. & Breimer, D. D. Role of environmental factors in the pharmacokinetics 
of drugs: considerations with respect to animal models, P-450 enzymes, and probe 
drugs. in Pharmacokinetics of Drugs (eds. Welling, P. G. & Balant, L. P.) 289–332,
Springer (1994). 
37. van Midwoud, P. M., Verpoorte, E. & Groothuis, G. M. M. Microfluidic devices for
in vitro studies on liver drug metabolism and toxicity. Integr. Biol. 3, 509–521 (2011).
38. Krishna, D. R. & Klotz, U. Extrahepatic metabolism of drugs in humans. Clin. 
Pharmacokinet. 26, 144–160 (1994).
39. Brandon, E. F. A., Raap, C. D., Meijerman, I., Beijnen, J. H. & Schellens, J. H. M. An 
update on in vitro test methods in human hepatic drug biotransformation research: pros 
and cons. Toxicol. Appl. Pharmacol. 189, 233–246 (2003).
40. Bjornsson, T. D. et al. The conduct of in vitro and in vivo drug-drug interaction studies: 
a pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug 
Metab. Dispos. 31, 815–832 (2003).
41. Raucy, J. L. & Lasker, J. M. Isolation of P450 enzymes from human liver. in Methods 
in Enzymology vol. 206 577–587, Academic Press (1991).
42. Soars, M. G., Burchell, B. & Riley, R. J. In vitro analysis of human drug 
glucuronidation and prediction of in vivo metabolic clearance. J. Pharmacol. Exp. 
Ther. 301, 382–390 (2002).
43. Boase, S. & Miners, J. O. In vitro–in vivo correlations for drugs eliminated by 
glucuronidation: Investigations with the model substrate zidovudine. Br. J. Clin. 
Pharmacol. 54, 493–503 (2002).
44. Liu, Y. & Coughtrie, M. W. H. Revisiting the latency of uridine diphosphate-
glucuronosyltransferases (UGTs)—How does the endoplasmic reticulum membrane 
influence their function? Pharmaceutics 9, 32 (2017).
78
45. Fisher, M. B., Campanale, K., Ackermann, B. L., VandenBranden, M. & Wrighton, S. 
A. In vitro glucuronidation using human liver microsomes and the pore-forming 
peptide alamethicin. Drug Metab. Dispos. 28, 560–566 (2000).
46. Rowland, A., Gaganis, P., Elliot, D. J., Mackenzie, P. I., Knights, K. M. & Miners, J. 
O. Binding of inhibitory fatty acids is responsible for the enhancement of UDP-
glucuronosyltransferase 2B7 activity by albumin: Implications for in vitro-in vivo 
extrapolation. J. Pharmacol. Exp. Ther. 321, 137–147 (2007).
47. Rowland, A., Knights, K. M., Mackenzie, P. I. & Miners, J. O. The ‘albumin effect’ 
and drug glucuronidation: bovine serum albumin and fatty acid-free human serum 
albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 
substrates but not UGT1A1 and UGT1A6 activities. Drug Metab. Dispos. Biol. Fate 
Chem. 36, 1056–1062 (2008).
48. Manevski, N., Moreolo, P. S., Yli-Kauhaluoma, J. & Finel, M. Bovine serum albumin 
decreases KM values of human UDP-glucuronosyltransferases 1A9 and 2B7 and 
increases VMAX values of UGT1A9. Drug Metab. Dispos. 39, 2117–2129 (2011).
49. Engtrakul, J. J., Foti, R. S., Strelevitz, T. J. & Fisher, M. B. Altered Azt (3′-azido-3′-
deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for 
underprediction of in vivo clearance: comparison to hepatocytes and effect of 
incubation environment. Drug Metab. Dispos. 33, 1621–1627 (2005).
50. Rodríguez-Antona, C., Donato, M. T., Boobis, A., Edwards, R. J., Watts, P. S., Castell, 
J. V. & Gómez-Lechón, M.-J. Cytochrome P450 expression in human hepatocytes and 
hepatoma cell lines: molecular mechanisms that determine lower expression in 
cultured cells. Xenobiotica Fate Foreign Compd. Biol. Syst. 32, 505–520 (2002).
51. Bell, C. C., Lauschke, V. M., Vorrink, S. U., Palmgren, H., Duffin, R., Andersson, T. 
B. & Ingelman-Sundberg, M. Transcriptional, functional, and mechanistic 
comparisons of stem cell–derived hepatocytes, HepaRG cells, and three-dimensional 
human hepatocyte spheroids as predictive in vitro systems for drug-induced liver 
injury. Drug Metab. Dispos. 45, 419–429 (2017).
52. Ma, L.-D., Wang, Y.-T., Wang, J.-R., Wu, J.-L., Meng, X.-S., Hu, P., Mu, X., Liang, 
Q.-L. & Luo, G.-A. Design and fabrication of a liver-on-a-chip platform for 
convenient, highly efficient, and safe in situ perfusion culture of 3D hepatic spheroids. 
Lab. Chip 18, 2547–2562 (2018).
53. Esch, M. B., Ueno, H., Applegate, D. R. & Shuler, M. L. Modular, pumpless body-on-
a-chip platform for the co-culture of GI tract epithelium and 3D primary liver tissue. 
Lab. Chip 16, 2719–2729 (2016).
54. Laskin, D. L. Parenchymal and nonparenchymal cell interactions in hepatotoxicity. in 
Biological Reactive Intermediates IV: Molecular and Cellular Effects and Their 
Impact on Human Health (eds. Witmer, C. M., Snyder, R. R., Jollow, D. J., Kalf, G. 
F., Kocsis, J. J. & Sipes, I. G.) 499–505, Springer New York (1991).
55. Edwards, R. J., Price, R. J., Watts, P. S., Renwick, A. B., Tredger, J. M., Boobis, A. 
R. & Lake, B. G. Induction of cytochrome P450 enzymes in cultured precision-cut 
human liver slices. Drug Metab. Dispos. 31, 282–288 (2003).
79
56. Martin, H., Sarsat, J.-P., de Waziers, I., Housset, C., Balladur, P., Beaune, P., 
Albaladejo, V. & Lerche-Langrand, C. Induction of cytochrome P450 2B6 and 3A4 
expression by phenobarbital and cyclophosphamide in cultured human liver slices. 
Pharm. Res. 20, 557–568 (2003).
57. Lu, C., Li, P., Gallegos, R., Uttamsingh, V., Xia, C. Q., Miwa, G. T., Balani, S. K. & 
Gan, L.-S. Comparison of intrinsic clearance in liver microsomes and hepatocytes 
from rats and humans: Evaluation of free fraction and uptake in hepatocytes. Drug 
Metab. Dispos. 34, 1600–1605 (2006).
58. Stringer, R., Nicklin, P. L. & Houston, J. B. Reliability of human cryopreserved 
hepatocytes and liver microsomes as in vitro systems to predict metabolic clearance. 
Xenobiotica Fate Foreign Compd. Biol. Syst. 38, 1313–1329 (2008).
59. Ge, S., Tu, Y. & Hu, M. Challenges and opportunities with predicting in vivo phase II 
metabolism via glucuronidation from in vitro data. Curr. Pharmacol. Rep. 2, 326–338
(2016).
60. Carreau, A., Hafny-Rahbi, B. E., Matejuk, A., Grillon, C. & Kieda, C. Why is the 
partial oxygen pressure of human tissues a crucial parameter? Small molecules and 
hypoxia. J. Cell. Mol. Med. 15, 1239–1253 (2011).
61. Mohyeldin, A., Garzón-Muvdi, T. & Quiñones-Hinojosa, A. Oxygen in stem cell 
biology: A critical component of the stem cell niche. Cell Stem Cell 7, 150–161 (2010).
62. Semenza, G. L. Oxygen sensing, homeostasis, and disease. N. Engl. J. Med. 365, 537–
547 (2011).
63. Brooks, A. J., Eastwood, J., Beckingham, I. J. & Girling, K. J. Liver tissue partial 
pressure of oxygen and carbon dioxide during partial hepatectomy. Br. J. Anaesth. 92,
735–737 (2004).
64. Brooks, A. J., Hammond, J. S., Girling, K. & Beckingham, I. J. The effect of hepatic 
vascular inflow occlusion on liver tissue pH, carbon dioxide, and oxygen partial 
pressures: defining the optimal clamp/release regime for intermittent portal clamping. 
J. Surg. Res. 141, 247–251 (2007).
65. Jones, D. P. Hypoxia and drug metabolism. Biochem. Pharmacol. 30, 1019–1023
(1981).
66. Jones, D. P., Aw, T. Y. & Shan, X. Drug metabolism and toxicity during hypoxia. 
Drug Metab. Rev. 20, 247–260 (1989).
67. Jones, D. P. & Mason, H. S. Gradients of O2 concentration in hepatocytes. J. Biol. 
Chem. 253, 4874–4880 (1978).
68. Le Couteur, D. G. & McLean, A. J. The aging liver: Drug clearance and an oxygen 
diffusion barrier hypothesis. Clin. Pharmacokinet. 34, 359–373 (1998).
69. Veal, G. J. & Back, D. J. Metabolism of zidovudine. Gen. Pharmacol. Vasc. Syst. 26,
1469–1475 (1995).
70. Urban, P. L., Goodall, D. M. & Bruce, N. C. Enzymatic microreactors in chemical 
analysis and kinetic studies. Biotechnol. Adv. 24, 42–57 (2006).
71. Cohen, C. B., Chin-Dixon, E., Jeong, S. & Nikiforov, T. T. A microchip-based enzyme 
assay for protein kinase a. Anal. Biochem. 273, 89–97 (1999).
80
72. Mao, H., Yang, T. & Cremer, P. S. Design and characterization of immobilized 
enzymes in microfluidic systems. Anal. Chem. 74, 379–385 (2002).
73. Hadd, A. G., Raymond, D. E., Halliwell, J. W., Jacobson, S. C. & Ramsey, J. M. 
Microchip device for performing enzyme assays. Anal. Chem. 69, 3407–3412 (1997).
74. Mao, S., Gao, D., Liu, W., Wei, H. & Lin, J.-M. Imitation of drug metabolism in human 
liver and cytotoxicity assay using a microfluidic device coupled to mass spectrometric 
detection. Lab. Chip 12, 219–226 (2011).
75. Ma, B., Zhang, G., Qin, J. & Lin, B. Characterization of drug metabolites and 
cytotoxicity assay simultaneously using an integrated microfluidic device. Lab. Chip
9, 232–238 (2009).
76. Baess, D., Jänig, G. R. & Ruckpaul, K. Interaction of the components of the 
cytochrome P-450 monooxygenase system from liver microsomes. I. Immobilization 
of the solubilized and partially purified protein components. Acta Biol. Med. Ger. 34,
1745–1754 (1975).
77. Eremin, A. N., Usanov, S. A. & Mterlitsa, D. I. Immobilization of highly purified 
cytochrome P-450 from microsomes of rabbit liver. Prikl. Biokhim. Mikrobiol. 15,
861–868 (1979).
78. Sheldon, R. A. Enzyme immobilization: The quest for optimum performance. Adv. 
Synth. Catal. 349, 1289–1307 (2007).
79. Wong, L. S., Khan, F. & Micklefield, J. Selective covalent protein immobilization: 
strategies and applications. Chem. Rev. 109, 4025–4053 (2009).
80. Jesionowski, T., Zdarta, J. & Krajewska, B. Enzyme immobilization by adsorption: a 
review. Adsorption 20, 801–821 (2014).
81. Mattiasson, B. Affinity immobilization. In Methods in Enzymology 647–656,
Academic Press (1988).
82. Green, N. M. Avidin. Adv. Protein Chem. 29, 85–133 (1975).
83. Hermanson, G. T. Chapter 1 - Functional targets. In Bioconjugate Techniques (Second 
Edition) (ed. Hermanson, G. T.) 1–168, Academic Press (2008).
84. Hermanson, G. T. Chapter 3 - The reactions of bioconjugation. in Bioconjugate 
Techniques (Third Edition) (ed. Hermanson, G. T.) 229–258, Academic Press (2013).
85. Luo, Q., Mao, X., Kong, L., Huang, X. & Zou, H. High-performance affinity 
chromatography for characterization of human immunoglobulin G digestion with 
papain. J. Chromatogr. B 776, 139–147 (2002).
86. Datta, S., Christena, L. R. & Rajaram, Y. R. S. Enzyme immobilization: an overview 
on techniques and support materials. 3 Biotech 3, 1–9 (2013).
87. Kim, D. & Herr, A. E. Protein immobilization techniques for microfluidic assays. 
Biomicrofluidics 7, 041501 (2013).
88. Sheldon, R. A. & Pelt, S. van. Enzyme immobilisation in biocatalysis: Why, what and 
how. Chem. Soc. Rev. 42, 6223–6235 (2013).
89. Zguris, J. C., Itle, L. J., Hayes, D. & Pishko, M. V. Microreactor microfluidic systems 
with human microsomes and hepatocytes for use in metabolite studies. Biomed. 
Microdevices 7, 117–125 (2005).
81
90. Sakai-Kato, K., Kato, M., Homma, H., Toyo’oka, T. & Utsunomiya-Tate, N. Creation 
of a P450 array toward high-throughput analysis. Anal. Chem. 77, 7080–7083 (2005).
91. Yang, H., Zheng, Y., Zhao, B., Shao, T., Shi, Q., Zhou, N. & Cai, W. Encapsulation 
of liver microsomes into a thermosensitive hydrogel for characterization of drug 
metabolism and toxicity. Biomaterials 34, 9770–9778 (2013).
92. Lee, J., Kim, S. H., Kim, Y.-C., Choi, I. & Sung, J. H. Fabrication and characterization 
of microfluidic liver-on-a-chip using microsomal enzymes. Enzyme Microb. Technol.
53, 159–164 (2013).
93. Wu, Q., Gao, D., Wei, J., Jin, F., Xie, W., Jiang, Y. & Liu, H. Development of a novel 
multi-layer microfluidic device towards characterization of drug metabolism and 
cytotoxicity for drug screening. Chem. Commun. 50, 2762–2764 (2014).
94. Lee, J., Choi, J., Ha, S. K., Choi, I., Lee, S. H., Kim, D., Choi, N. & Sung, J. H. A 
microfluidic device for evaluating the dynamics of the metabolism-dependent 
antioxidant activity of nutrients. Lab. Chip 14, 2948–2957 (2014).
95. Ueda, Y., Morigaki, K., Tatsu, Y., Yumoto, N. & Imaishi, H. Immobilization and 
activity assay of cytochrome P450 on patterned lipid membranes. Biochem. Biophys. 
Res. Commun. 355, 926–931 (2007).
96. Schejbal, J., Řemínek, R., Zeman, L., Mádr, A. & Glatz, Z. On-line coupling of 
immobilized cytochrome P450 microreactor and capillary electrophoresis: A 
promising tool for drug development. J. Chromatogr. A 1437, 234–240 (2016).
97. Nicoli, R., Bartolini, M., Rudaz, S., Andrisano, V. & Veuthey, J.-L. Development of 
immobilized enzyme reactors based on human recombinant cytochrome P450 
enzymes for phase I drug metabolism studies. J. Chromatogr. A 1206, 2–10 (2008).
98. Früh, V., IJzerman, A. P. & Siegal, G. How to catch a membrane protein in action: A
review of functional membrane protein immobilization strategies and their 
applications. Chem. Rev. 111, 640–656 (2011).
99. Wollenberg, L. A., Kabulski, J. L., Powell, M. J., Chen, J., Flora, D. R., Tracy, T. S. 
& Gannett, P. M. The use of immobilized cytochrome P4502C9 in PMMA-based plug 
flow bioreactors for the production of drug metabolites. Appl. Biochem. Biotechnol.
172, 1293–1306 (2014).
100. Ménard, A., Huang, Y., Karam, P., Cosa, G. & Auclair, K. Site-specific fluorescent 
labeling and oriented immobilization of a triple mutant of CYP3A4 via c64. Bioconjug. 
Chem. 23, 826–836 (2012).
101. Gannett, P. M., Kabulski, J., Perez, F. A., Liu, Z., Lederman, D., Locuson, C. W., 
Ayscue, R. R., Thomsen, N. M. & Tracy, T. S. Preparation, characterization, and 
substrate metabolism of gold-immobilized cytochrome P450 2C9. J. Am. Chem. Soc.
128, 8374–8375 (2006).
102. Tan, C. Y., Hirakawa, H. & Nagamune, T. Supramolecular protein assembly supports 
immobilization of a cytochrome P450 monooxygenase system as water-insoluble gel. 
Sci. Rep. 5, 8648 (2015).
103. Schneider, E. & Clark, D. S. Cytochrome P450 (CYP) enzymes and the development 
of CYP biosensors. Biosens. Bioelectron. 39, 1–13 (2013).
82
104. Manz, A., Graber, N. & Widmer, H. M. Miniaturized total chemical analysis systems: 
A novel concept for chemical sensing. Sens. Actuators B Chem. 1, 244–248 (1990).
105. Pandey, C. M., Augustine, S., Kumar, S., Kumar, S., Nara, S., Srivastava, S. & 
Malhotra, B. D. Microfluidics based point-of-care diagnostics. Biotechnol. J. 13,
(2018).
106. Sung, J. H., Wang, Y. I., Sriram, N. N., Jackson, M., Long, C., Hickman, J. J. & Shuler, 
M. L. Recent advances in body-on-a-chip systems. Anal. Chem. 91, 330–351 (2019).
107. Nys, G. & Fillet, M. Microfluidics contribution to pharmaceutical sciences: From drug 
discovery to post marketing product management. J. Pharm. Biomed. Anal. 159, 348–
362 (2018).
108. Dittrich, P. S. & Manz, A. Lab-on-a-chip: microfluidics in drug discovery. Nat. Rev. 
Drug Discov. 5, 210–218 (2006).
109. Culbertson, C. T., Mickleburgh, T. G., Stewart-James, S. A., Sellens, K. A. & 
Pressnall, M. Micro total analysis systems: fundamental advances and biological 
applications. Anal. Chem. 86, 95–118 (2014).
110. Reyes, D. R., Iossifidis, D., Auroux, P.-A. & Manz, A. Micro total analysis systems. 
1. Introduction, theory, and technology. Anal. Chem. 74, 2623–2636 (2002).
111. Becker, H. & Gärtner, C. Polymer microfabrication technologies for microfluidic 
systems. Anal. Bioanal. Chem. 390, 89–111 (2008).
112. Xia, Y. & Whitesides, G. M. Soft lithography. Annu. Rev. Mater. Sci. 28, 153–184
(1998).
113. Duffy, D. C., McDonald, J. C., Schueller, O. J. A. & Whitesides, G. M. Rapid 
prototyping of microfluidic systems in poly(dimethylsiloxane). Anal. Chem. 70, 4974–
4984 (1998).
114. Franssila, S. Optical Lithography. In Introduction to Microfabrication 103–113, John 
Wiley & Sons, Ltd (2010).
115. Lin, C.-H., Lee, G.-B., Chang, B.-W. & Chang, G.-L. A new fabrication process for 
ultra-thick microfluidic microstructures utilizing SU-8 photoresist. J. Micromechanics 
Microengineering 12, 590–597 (2002).
116. Sikanen, T., Tuomikoski, S., Ketola, R. A., Kostiainen, R., Franssila, S. & Kotiaho, T. 
Characterization of SU-8 for electrokinetic microfluidic applications. Lab. Chip 5,
888–896 (2005).
117. Yang, L., Hao, X., Wang, C., Zhang, B. & Wang, W. Rapid and low cost replication 
of complex microfluidic structures with PDMS double casting technology. Microsyst. 
Technol. 20, 1933–1940 (2014).
118. McCormick, R. M., Nelson, R. J., Alonso-Amigo, M. G., Benvegnu, D. J. & Hooper, 
H. H. Microchannel electrophoretic separations of DNA in injection-molded plastic 
substrates. Anal. Chem. 69, 2626–2630 (1997).
119. Becker, H. & Heim, U. Hot embossing as a method for the fabrication of polymer high 
aspect ratio structures. Sens. Actuators Phys. 83, 130–135 (2000).
83
120. McDonald, J. C., Duffy, D. C., Anderson, J. R., Chiu, D. T., Wu, H., Schueller, O. J. 
A. & Whitesides, G. M. Fabrication of microfluidic systems in 
poly(dimethylsiloxane). Electrophoresis 21, 27–40 (2000).
121. Tähkä, S., Sarfraz, J., Urvas, L., Provenzani, R., Wiedmer, S. K., Peltonen, J., Jokinen, 
V. & Sikanen, T. Immobilization of proteolytic enzymes on replica-molded thiol-ene 
micropillar reactors via thiol-gold interaction. Anal. Bioanal. Chem. 411, 2339–2349
(2019).
122. Ren, K., Zhou, J. & Wu, H. Materials for microfluidic chip fabrication. Acc. Chem. 
Res. 46, 2396–2406 (2013).
123. Lee, J. N., Park, C. & Whitesides, G. M. Solvent compatibility of 
poly(dimethylsiloxane)-based microfluidic devices. Anal. Chem. 75, 6544–6554
(2003).
124. Toepke, M. W. & Beebe, D. J. PDMS absorption of small molecules and consequences 
in microfluidic applications. Lab. Chip 6, 1484–1486 (2006).
125. van Midwoud, P. M., Janse, A., Merema, M. T., Groothuis, G. M. M. & Verpoorte, E. 
Comparison of biocompatibility and adsorption properties of different plastics for 
advanced microfluidic cell and tissue culture models. Anal. Chem. 84, 3938–3944
(2012).
126. Morra, M., Occhiello, E., Marola, R., Garbassi, F., Humphrey, P. & Johnson, D. On 
the aging of oxygen plasma-treated polydimethylsiloxane surfaces. J. Colloid 
Interface Sci. 137, 11–24 (1990).
127. Chen, Y., Zhang, L. & Chen, G. Fabrication, modification, and application of 
poly(methyl methacrylate) microfluidic chips. Electrophoresis 29, 1801–1814 (2008).
128. Shadpour, H., Hupert, M. L., Patterson, D., Liu, C., Galloway, M., Stryjewski, W., 
Goettert, J. & Soper, S. A. Multichannel microchip electrophoresis device fabricated 
in polycarbonate with an integrated contact conductivity sensor array. Anal. Chem. 79,
870–878 (2007).
129. Sticker, D., Geczy, R., Häfeli, U. O. & Kutter, J. P. Thiol–ene based polymers as 
versatile materials for microfluidic devices for life sciences applications. ACS Appl. 
Mater. Interfaces 12, 10080–10095 (2020).
130. Goddard, J. M. & Hotchkiss, J. H. Polymer surface modification for the attachment of 
bioactive compounds. Prog. Polym. Sci. 32, 698–725 (2007).
131. Makamba, H., Kim, J. H., Lim, K., Park, N. & Hahn, J. H. Surface modification of 
poly(dimethylsiloxane) microchannels. Electrophoresis 24, 3607–3619 (2003).
132. Brown, L., Koerner, T., Horton, J. H. & Oleschuk, R. D. Fabrication and 
characterization of poly(methylmethacrylate) microfluidic devices bonded using 
surface modifications and solvents. Lab. Chip 6, 66–73 (2006).
133. Chan, C.-M., Ko, T.-M. & Hiraoka, H. Polymer surface modification by plasmas and 
photons. Surf. Sci. Rep. 24, 1–54 (1996).
134. Situma, C., Wang, Y., Hupert, M., Barany, F., McCarley, R. L. & Soper, S. A. 
Fabrication of DNA microarrays onto poly(methyl methacrylate) with ultraviolet 
84
patterning and microfluidics for the detection of low-abundant point mutations. Anal. 
Biochem. 340, 123–135 (2005).
135. Carlborg, C. F., Haraldsson, T., Öberg, K., Malkoch, M. & Wijngaart, W. van der. 
Beyond PDMS: off-stoichiometry thiol–ene (OSTE) based soft lithography for rapid 
prototyping of microfluidic devices. Lab. Chip 11, 3136–3147 (2011).
136. Machado, T. O., Sayer, C. & Araujo, P. H. H. Thiol-ene polymerisation: A promising 
technique to obtain novel biomaterials. Eur. Polym. J. 86, 200–215 (2017).
137. Hoyle, C. E. & Bowman, C. N. Thiol-ene click chemistry. Angew. Chem. Int. Ed. 49,
1540–1573 (2010).
138. Khire, V. S., Yi, Y., Clark, N. A. & Bowman, C. N. Formation and surface 
modification of nanopatterned thiol-ene substrates using step and flash imprint 
lithography. Adv. Mater. 20, 3308–3313 (2008).
139. Ashley, J. F., Cramer, N. B., Davis, R. H. & Bowman, C. N. Soft-lithography 
fabrication of microfluidic features using thiol-ene formulations. Lab. Chip 11, 2772 
(2011).
140. Tähkä, S. M., Bonabi, A., Nordberg, M.-E., Kanerva, M., Jokinen, Ville. P. & Sikanen, 
T. M. Thiol-ene microfluidic devices for microchip electrophoresis: Effects of curing 
conditions and monomer composition on surface properties. J. Chromatogr. A 1426,
233–240 (2015).
141. Sticker, D., Rothbauer, M., Lechner, S., Hehenberger, M.-T. & Ertl, P. Multi-layered, 
membrane-integrated microfluidics based on replica molding of a thiol–ene epoxy 
thermoset for organ-on-a-chip applications. Lab. Chip 15, 4542–4554 (2015).
142. Jönsson, A., Svejdal, R. R., Bøgelund, N., Nguyen, T. T. T. N., Flindt, H., Kutter, J. 
P., Rand, K. D. & Lafleur, J. P. Thiol-ene monolithic pepsin microreactor with a 3D-
printed interface for efficient UPLC-MS peptide mapping analyses. Anal. Chem. 89,
4573–4580 (2017).
143. Hoffmann, C., Pinelo, M., Woodley, J. M. & Daugaard, A. E. Development of a thiol-
ene based screening platform for enzyme immobilization demonstrated using 
horseradish peroxidase. Biotechnol. Prog. 33, 1267–1277 (2017).
144. Lafleur, J. P., Kwapiszewski, R., Jensen, T. G. & Kutter, J. P. Rapid photochemical 
surface patterning of proteins in thiol–ene based microfluidic devices. Analyst 138,
845–849 (2013).
145. Feidenhans’l, N. A., Lafleur, J. P., Jensen, T. G. & Kutter, J. P. Surface functionalized 
thiol-ene waveguides for fluorescence biosensing in microfluidic devices. 
Electrophoresis 35, 282–288 (2014).
146. Çakmakçi, E., Yuce-Dursun, B. & Demir, S. Maleic anhydride functionalization of 
OSTE based coatings via thiol-ene “Click” reaction for the covalent immobilization of 
xylanase. React. Funct. Polym. 111, 38–43 (2017).
147. Jonkheijm, P., Weinrich, D., Köhn, M., Engelkamp, H., Christianen, P. C. M., 
Kuhlmann, J., Maan, J. C., Nüsse, D., Schroeder, H., Wacker, R., Breinbauer, R., 
Niemeyer, C. M. & Waldmann, H. Photochemical surface patterning by the thiol-ene 
reaction. Angew. Chem. Int. Ed. 47, 4421–4424 (2008).
85
148. Lafleur, J. P., Senkbeil, S., Novotny, J., Nys, G., Bøgelund, N., Rand, K. D., Foret, F. 
& Kutter, J. P. Rapid and simple preparation of thiol-ene emulsion-templated 
monoliths and their application as enzymatic microreactors. Lab. Chip 15, 2162–2172
(2015).
149. Bataille, J., Viodé, A., Pereiro, I., Lafleur, J. P., Varenne, F., Descroix, S., Becher, F., 
Kutter, J. P., Roesch, C., Poüs, C., Taverna, M., Pallandre, A., Smadja, C. & Le Potier, 
I. On-a-chip tryptic digestion of transthyretin: a step toward an integrated microfluidic 
system for the follow-up of familial transthyretin amyloidosis. The Analyst 143, 1077–
1086 (2018).
150. Temiz, Y., Lovchik, R. D., Kaigala, G. V. & Delamarche, E. Lab-on-a-chip devices: 
How to close and plug the lab? Microelectron. Eng. 132, 156–175 (2015).
151. Satyanarayana, S., Karnik, R. N. & Majumdar, A. Stamp-and-stick room-temperature 
bonding technique for microdevices. J. Microelectromechanical Syst. 14, 392–399 
(2005).
152. Sandström, N., Shafagh, R. Z., Vastesson, A., Carlborg, C. F., Wijngaart, W. van der 
& Haraldsson, T. Reaction injection molding and direct covalent bonding of OSTE+
polymer microfluidic devices. J. Micromechanics Microengineering 25, 075002 
(2015).
153. Cramer, N. B., Scott, J. P. & Bowman, C. N. Photopolymerizations of thiol−ene 
polymers without photoinitiators. Macromolecules 35, 5361–5365 (2002).
154. Sikanen, T. M., Lafleur, J. P., Moilanen, M.-E., Zhuang, G., Jensen, T. G. & Kutter, J. 
P. Fabrication and bonding of thiol-ene-based microfluidic devices. J. 
Micromechanics Microengineering 23, 037002 (2013).
155. Huikko, K., Östman, P., Grigoras, K., Tuomikoski, S., Tiainen, V.-M., Soininen, A., 
Puolanne, K., Manz, A., Franssila, S., Kostiainen, R. & Kotiaho, T. 
Poly(dimethylsiloxane) electrospray devices fabricated with diamond-like carbon–
poly(dimethylsiloxane) coated su-8 masters. Lab. Chip 3, 67–72 (2003).
156. Tähkä, S. M., Bonabi, A., Jokinen, V. P. & Sikanen, T. M. Aqueous and non-aqueous 
microchip electrophoresis with on-chip electrospray ionization mass spectrometry on 
replica-molded thiol-ene microfluidic devices. J. Chromatogr. A 1496, 150–156
(2017).
157. Kampe, T., König, A., Schroeder, H., Hengstler, J. G. & Niemeyer, C. M. Modular 
microfluidic system for emulation of human phase I/phase II metabolism. Anal. Chem.
86, 3068–3074 (2014).
158. Peterson, D. S., Rohr, T., Svec, F. & Fréchet, J. M. J. Enzymatic microreactor-on-a-
chip:  protein mapping using trypsin immobilized on porous polymer monoliths 
molded in channels of microfluidic devices. Anal. Chem. 74, 4081–4088 (2002).
159. Oliver-Calixte, N. J., Uba, F. I., Battle, K. N., Weerakoon-Ratnayake, K. M. & Soper, 
S. A. Immobilization of lambda exonuclease onto polymer micropillar arrays for the 
solid-phase digestion of ds-DNAs. Anal. Chem. 86, 4447–4454 (2014).
86
160. Slovakova, M., Minc, N., Bilkova, Z., Smadja, C., Faigle, W., Fütterer, C., Taverna, 
M. & Viovy, J.-L. Use of self assembled magnetic beads for on-chip protein digestion. 
Lab. Chip 5, 935–942 (2005).
161. Losey, M. W., Jackman, R. J., Firebaugh, S. L., Schmidt, M. A. & Jensen, K. F. Design 
and fabrication of microfluidic devices for multiphase mixing and reaction. J. 
Microelectromechanical Syst. 11, 709–717 (2002).
162. Haapala, M., Saarela, V., Pól, J., Kolari, K., Kotiaho, T., Franssila, S. & Kostiainen, 
R. Integrated liquid chromatography–heated nebulizer microchip for mass 
spectrometry. Anal. Chim. Acta 662, 163–169 (2010).
163. Vlakh, E. G. & Tennikova, T. B. Flow-through immobilized enzyme reactors based on 
monoliths: II. Kinetics study and application. J. Sep. Sci. 36, 1149–1167 (2013).
164. Munirathinam, R., Huskens, J. & Verboom, W. Supported catalysis in continuous-flow 
microreactors. Adv. Synth. Catal. 357, 1093–1123 (2015).
165. Tallarek, U., Rapp, E., Scheenen, T., Bayer, E. & Van As, H. Electroosmotic and 
pressure-driven flow in open and packed capillaries:  velocity distributions and fluid 
dispersion. Anal. Chem. 72, 2292–2301 (2000).
166. Kutter, J. P., Mogensen, K. B., Klank, H. & Geschke, O. Microfluidics – Components. 
In Microsystem Engineering of Lab-on-a-Chip Devices 39–77, John Wiley & Sons, 
Ltd (2004).
167. Li, S. F. Y. Chapter 1 Introduction. In Capillary Electrophoresis vol. 52 1–30, Elsevier
(1992).
168. Miserendino, S. & Tai, Y.-C. Pressure-driven microfluidics. In Micro/Nano 
Technology Systems for Biomedical Applications: Microfluidics, Optics, and Surface 
Chemistry, Oxford University Press (2010).
169. Wang, Y.-N. & Fu, L.-M. Micropumps and biomedical applications – A review. 
Microelectron. Eng. 195, 121–138 (2018).
170. Unger, M. A., Chou, H.-P., Thorsen, T., Scherer, A. & Quake, S. R. Monolithic 
microfabricated valves and pumps by multilayer soft lithography. Science 288, 113–
116 (2000).
171. Zhou, J. & Poloyac, S. M. The effect of therapeutic hypothermia on drug metabolism 
and drug response: cellular mechanisms to organ function. Expert Opin. Drug Metab. 
Toxicol. 7, 803–816 (2011).
172. Mogensen, K. B. & Kutter, J. P. Optical detection in microfluidic systems. 
Electrophoresis 30, S92–S100 (2009).
173. Vandaveer, W. R., Pasas-Farmer, S. A., Fischer, D. J., Frankenfeld, C. N. & Lunte, S. 
M. Recent developments in electrochemical detection for microchip capillary 
electrophoresis. Electrophoresis 25, 3528–3549 (2004).
174. Kubán, P. & Hauser, P. C. Fundamentals of electrochemical detection techniques for 
CE and MCE. Electrophoresis 30, 3305–3314 (2009).
175. Sikanen, T., Tuomikoski, S., Ketola, R. A., Kostiainen, R., Franssila, S. & Kotiaho, T. 
Fully microfabricated and integrated SU-8-based capillary electrophoresis-
87
electrospray ionization microchips for mass spectrometry. Anal. Chem. 79, 9135–9144 
(2007).
176. Nordman, N., Sikanen, T., Moilanen, M.-E., Aura, S., Kotiaho, T., Franssila, S. & 
Kostiainen, R. Rapid and sensitive drug metabolism studies by SU-8 microchip 
capillary electrophoresis-electrospray ionization mass spectrometry. J. Chromatogr. A
1218, 739–745 (2011).
177. Sakai-Kato, K., Kato, M. & Toyo’oka, T. Screening of inhibitors of uridine 
diphosphate glucuronosyltransferase with a miniaturized on-line drug-metabolism 
system. J. Chromatogr. A 1051, 261–266 (2004).
178. Alebić-Kolbah, T. & Wainer, I. W. Microsomal immobilized-enzyme-reactor for on-
line production of glucuronides in a HPLC column. Chromatographia 37, 608–612 
(1993).
179. Kim, H. S. & Wainer, I. W. The covalent immobilization of microsomal uridine 
diphospho-glucuronosyltransferase (UDPGT): Initial synthesis and characterization of 
an UDPGT immobilized enzyme reactor for the on-line study of glucuronidation. J. 
Chromatogr. B 823, 158–166 (2005).
180. Sticker, D., Rothbauer, M., Ehgartner, J., Steininger, C., Liske, O., Liska, R., Neuhaus, 
W., Mayr, T., Haraldsson, T., Kutter, J. P. & Ertl, P. Oxygen management at the 
microscale: A functional biochip material with long-lasting and tunable oxygen 
scavenging properties for cell culture applications. ACS Appl. Mater. Interfaces 11,
9730–9739 (2019).
181. Csiszár, A., Hersch, N., Dieluweit, S., Biehl, R., Merkel, R. & Hoffmann, B. Novel 
fusogenic liposomes for fluorescent cell labeling and membrane modification. 
Bioconjug. Chem. 21, 537–543 (2010).
182. Hersch, N., Wolters, B., Ungvari, Z., Gautam, T., Deshpande, D., Merkel, R., Csiszar, 
A., Hoffmann, B. & Csiszár, A. Biotin-conjugated fusogenic liposomes for high-
quality cell purification. J. Biomater. Appl. 30, 846–856 (2016).
183. Kiiski, I. M. A., Pihlaja, T., Urvas, L., Witos, J., Wiedmer, S. K., Jokinen, V. P. &
Sikanen, T. M. Overcoming the pitfalls of cytochrome P450 immobilization through 
the use of fusogenic liposomes. Adv. Biosyst. 3, 1800245 (2019).
184. Sikanen, T., Zwinger, T., Tuomikoski, S., Franssila, S., Lehtiniemi, R., Fager, C.-M.,
Kotiaho, T. & Pursula, A. Temperature modeling and measurement of an electrokinetic 
separation chip. Microfluid. Nanofluidics 5, 479–491 (2008).
185. Marmur, A. Soft contact: measurement and interpretation of contact angles. Soft 
Matter 2, 12–17 (2006).
186. Ellman, G. L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82, 70–77 (1959).
187. Eyer, P., Worek, F., Kiderlen, D., Sinko, G., Stuglin, A., Simeon-Rudolf, V. & Reiner, 
E. Molar absorption coefficients for the reduced Ellman reagent: reassessment. Anal. 
Biochem. 312, 224–227 (2003).
188. Sathyanarayanan, G., Haapala, M., Kiiski, I. & Sikanen, T. Digital microfluidic 
immobilized cytochrome P450 reactors with integrated inkjet-printed microheaters for 
88
droplet-based drug metabolism research. Anal. Bioanal. Chem. 410, 6677–6687
(2018).
189. Tiggelaar, R. M., Male, P. van, Berenschot, J. W., Gardeniers, J. G. E., Oosterbroek, 
R. E., Croon, M. H. J. M. de, Schouten, J. C., Berg, A. van den & Elwenspoek, M. C. 
Fabrication of a high-temperature microreactor with integrated heater and sensor 
patterns on an ultrathin silicon membrane. Sens. Actuators Phys. 119, 196–205 (2005).
190. Jeon, N. L., Dertinger, S. K. W., Chiu, D. T., Choi, I. S., Stroock, A. D. & Whitesides, 
G. M. Generation of solution and surface gradients using microfluidic systems. 
Langmuir 16, 8311–8316 (2000).
191. Cevc, G. & Richardsen, H. Lipid vesicles and membrane fusion. Adv. Drug Deliv. Rev.
38, 207–232 (1999).
192. Chernomordik, L. V. & Kozlov, M. M. Mechanics of membrane fusion. Nat. Struct. 
Mol. Biol. 15, 675–683 (2008).
193. Naumovska, E., Ludwanowski, S., Hersch, N., Braun, T., Merkel, R., Hoffmann, B. & 
Csiszár, A. Plasma membrane functionalization using highly fusogenic immune 
activator liposomes. Acta Biomater. 10, 1403–1411 (2014).
194. Kube, S., Hersch, N., Naumovska, E., Gensch, T., Hendriks, J., Franzen, A., Landvogt, 
L., Siebrasse, J.-P., Kubitscheck, U., Hoffmann, B., Merkel, R. & Csiszár, A. 
Fusogenic liposomes as nanocarriers for the delivery of intracellular proteins. 
Langmuir 33, 1051–1059 (2017).
195. Bailey, A. L. & Cullis, P. R. Membrane fusion with cationic liposomes: effects of 
target membrane lipid composition. Biochemistry 36, 1628–1634 (1997).
196. Chesnoy, S. & Huang, L. Structure and function of lipid-DNA complexes for gene 
delivery. Annu. Rev. Biophys. Biomol. Struct. 29, 27–47 (2000).
197. Bajoria, R. & Contractor, S. F. Effect of the size of liposomes on the transfer and 
uptake of carboxyfluorescein by the perfused human term placenta. J. Pharm. 
Pharmacol. 49, 675–681 (1997).
198. Malinin, V. S., Frederik, P. & Lentz, B. R. Osmotic and curvature stress affect PEG-
induced fusion of lipid vesicles but not mixing of their lipids. Biophys. J. 82, 2090–
2100 (2002).
199. Hoekstra, D., De Boer, T., Klappe, K. & Wilschut, J. Fluorescence method for 
measuring the kinetics of fusion between biological membranes. Biochemistry 23,
5675–5681 (1984).
200. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., 
Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J. & Klenk, D. C. 
Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76–85 (1985).
201. Hochman, Y., Zakim, D. & Vessey, D. A. A kinetic mechanism for modulation of the 
activity of microsomal UDP-glucuronyltransferase by phospholipids. Effects of 
lysophosphatidylcholines. J. Biol. Chem. 256, 4783–4788 (1981).
202. Palaiokostas, M., Ding, W., Shahane, G. & Orsi, M. Effects of lipid composition on 
membrane permeation. Soft Matter 14, 8496–8508 (2018).
89
203. Kiiski, I., Ollikainen, E., Artes, S., Järvinen, P., Jokinen, V. & Sikanen, T. Drug 
glucuronidation assays on human liver microsomes immobilized on microfluidic flow-
through reactors. Eur. J. Pharm. Sci. 158, 105677 (2021).
204. Ejserholm, F., Stegmayr, J., Bauer, P., Johansson, F., Wallman, L., Bengtsson, M. & 
Oredsson, S. Biocompatibility of a polymer based on off-stoichiometry thiol-
enes + epoxy (OSTE+) for neural implants. Biomater. Res. 19, 19 (2015).
205. Berry, L. M. & Zhao, Z. An examination of IC50 and IC50-shift experiments in 
assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human 
liver microsomes. Drug Metab. Lett. 2, 51–59 (2008).
206. Horspool, A. M., Wang, T., Scaringella, Y.-S., Taub, M. E. & Chan, T. S. Human liver 
microsomes immobilized on magnetizable beads: a novel approach to study in vitro
drug metabolism. Drug Metab. Dispos. 48, 645–654 (2020).
207. Kwisnek, L., Nazarenko, S. & Hoyle, C. E. Oxygen transport properties of thiol-ene 
networks. Macromolecules 42, 7031–7041 (2009).
208. Cramer, N. B. & Bowman, C. N. Kinetics of thiol-ene and thiol-acrylate 
photopolymerizations with real-time fourier transform infrared. J. Polym. Sci. Part 
Polym. Chem. 39, 3311–3319 (2001).
209. Vitale, A., Hennessy, M. G., Matar, O. K. & Cabral, J. T. A unified approach for 
patterning via frontal photopolymerization. Adv. Mater. 27, 6118–6124 (2015).
210. Brennan, M. D., Rexius-Hall, M. L., Elgass, L. J. & Eddington, D. T. Oxygen control 
with microfluidics. Lab. Chip 14, 4305–4318 (2014).
211. Oomen, P. E., Skolimowski, M. D. & Verpoorte, E. Implementing oxygen control in 
chip-based cell and tissue culture systems. Lab. Chip 16, 3394–3414 (2016).
212. Oppegard, S. C., Blake, A. J., Williams, J. C. & Eddington, D. T. Precise control over 
the oxygen conditions within the Boyden chamber using a microfabricated insert. Lab. 
Chip 10, 2366–2373 (2010).
213. Abaci, H. E., Devendra, R., Soman, R., Drazer, G. & Gerecht, S. Microbioreactors to 
manipulate oxygen tension and shear stress in the microenvironment of vascular stem 
and progenitor cells. Biotechnol. Appl. Biochem. 59, 97–105 (2012).
214. Skolimowski, M., Nielsen, M. W., Emnéus, J., Molin, S., Taboryski, R., Sternberg, C., 
Dufva, M. & Geschke, O. Microfluidic dissolved oxygen gradient generator biochip 
as a useful tool in bacterial biofilm studies. Lab. Chip 10, 2162–2169 (2010).
215. Peng, C.-C., Liao, W.-H., Chen, Y.-H., Wu, C.-Y. & Tung, Y.-C. A microfluidic cell 
culture array with various oxygen tensions. Lab. Chip 13, 3239–3245 (2013).
216. Cretton, E. M., Xie, M. Y., Bevan, R. J., Goudgaon, N. M., Schinazi, R. F. & 
Sommadossi, J. P. Catabolism of 3’-azido-3’-deoxythymidine in hepatocytes and liver 
microsomes, with evidence of formation of 3’-amino-3’-deoxythymidine, a highly 
toxic catabolite for human bone marrow cells. Mol. Pharmacol. 39, 258–266 (1991).
217. Pan-Zhou, X.-R., Cretton-Scott, E., Zhou, X.-J., Yang, M.-X., Lasker, J. M. & 
Sommadossi, J.-P. Role of human liver P450s and cytochrome b5 in the reductive 
metabolism of 3′-azido-3′-deoxythymidine (AZT) to 3′-amino-3′-deoxythymidine. 
Biochem. Pharmacol. 55, 757–766 (1998).
90
218. Eagling, V. A., Howe, J. L., Barry, M. J. & Back, D. J. The metabolism of zidovudine 
by human liver microsomes in vitro: Formation of 3′-amino-3′-deoxythymidine. 
Biochem. Pharmacol. 48, 267–276 (1994).
219. Fayz, S. & Inaba, T. Zidovudine azido-reductase in human liver microsomes: 
activation by ethacrynic acid, dipyridamole, and indomethacin and inhibition by 
human immunodeficiency virus protease inhibitors. Antimicrob. Agents Chemother.
42, 1654–1658 (1998).
220. Sathyanarayanan, G., Haapala, M. & Sikanen, T. Interfacing digital microfluidics with 
ambient mass spectrometry using SU-8 as dielectric layer. Micromachines 9, 649 
(2018).
221. Sathyanarayanan, G., Haapala, M. & Sikanen, T. Digital microfluidics-enabled 
analysis of individual variation in liver cytochrome P450 activity. Anal. Chem. 92,
14693–14701 (2020).
222. Pihlaja, T., Kiiski, I. & Sikanen, T. Mechanistic study of time-dependent cytochrome 
P450 inhibition using microfluidic immobilized enzyme assays. In Nordic POP 1st 
annual meeting (2019).
223. Senkbeil, S., Aho, J., Yde, L., Lindvold, L. R., Stensborg, J. F., Rantanen, J., Lafleur, 
J. P. & Kutter, J. P. Roll-to-plate fabrication of microfluidic devices with rheology-
modified thiol-ene resins. J. Micromechanics Microengineering 26, 075014 (2016).
